<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><?covid-19-tdm ?><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">100248</article-id><article-id pub-id-type="doi">10.7554/eLife.100248</article-id><article-id pub-id-type="doi" specific-use="version">10.7554/eLife.100248.3</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group></article-categories><title-group><article-title>SARS-CoV-2 NSP13 interacts with TEAD to suppress Hippo-YAP signaling</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Fansen</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3173-5512</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jong Hwan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Chang-Ru</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Steimle</surname><given-names>Jeffrey D</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund6"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Yufeng</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Rich G</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Bing</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Deshmukh</surname><given-names>Vaibhav</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shijie</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiao</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8527-4438</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Martin</surname><given-names>James F</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-7842-9857</contrib-id><email>jfmartin@bcm.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00r4vsg44</institution-id><institution>McGill Gene Editing Lab, The Texas Heart Institute</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00r4vsg44</institution-id><institution>Cardiomyocyte Renewal Laboratory, The Texas Heart Institute</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/02pttbw34</institution-id><institution>Department of Integrative Physiology, Baylor College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01hcyya48</institution-id><institution>The Heart Institute, Division of Molecular Cardiovascular Biology, Cincinnati Children's Hospital Medical Center</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e3m7079</institution-id><institution>Department of Pediatrics, University of Cincinnati College of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Lim</surname><given-names>Dae-Sik</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05apxxy63</institution-id><institution>Korea Advanced Institute of Science and Technology</institution></institution-wrap><country>Republic of Korea</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0165r2y73</institution-id><institution>Max Planck Institute for Heart and Lung Research</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>23</day><month>09</month><year>2025</year></pub-date><volume>13</volume><elocation-id>RP100248</elocation-id><history><date date-type="sent-for-review" iso-8601-date="2024-06-25"><day>25</day><month>06</month><year>2024</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint.</event-desc><date date-type="preprint" iso-8601-date="2024-08-15"><day>15</day><month>08</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2023.11.30.569413"/></event><event><event-desc>This manuscript was published as a reviewed preprint.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2024-08-21"><day>21</day><month>08</month><year>2024</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100248.1"/></event><event><event-desc>The reviewed preprint was revised.</event-desc><date date-type="reviewed-preprint" iso-8601-date="2025-08-14"><day>14</day><month>08</month><year>2025</year></date><self-uri content-type="reviewed-preprint" xlink:href="https://doi.org/10.7554/eLife.100248.2"/></event></pub-history><permissions><copyright-statement>Â© 2024, Meng et al</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>Meng et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-100248-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-100248-figures-v1.pdf"/><abstract><p>The Hippo pathway controls organ development, homeostasis, and regeneration primarily by modulating YAP/TEAD-mediated gene expression. Although emerging studies report Hippo-YAP dysfunction after viral infection, it is largely unknown in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here, we analyzed RNA sequencing data from human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) and SARS-CoV-2-infected human lung samples, and observed a decrease in YAP target gene expression. In screening SARS-CoV-2 nonstructural proteins, we found that nonstructural protein 13 (NSP13), a conserved coronavirus helicase, inhibits YAP transcriptional activity independent of the upstream Hippo kinases LATS1/2. Consistently, introducing NSP13 into mouse cardiomyocytes suppresses an active form of YAP (YAP5SA) <italic>in vivo</italic>. Subsequent investigations on NSP13 mutants revealed that NSP13 helicase activity, including DNA binding and unwinding, is crucial for suppressing YAP transactivation in HEK293T cells. Mechanistically, TEAD4 serves as a platform to recruit NSP13 and YAP. NSP13 likely inactivates the YAP/TEAD4 transcription complex by remodeling chromatin to recruit proteins, such as transcription termination factor 2 (TTF2), to bind the YAP/TEAD/NSP13 complex. These findings reveal a novel YAP/TEAD regulatory mechanism and uncover molecular insights into Hippo-YAP regulation after SARS-CoV-2 infection in humans.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>SARS-CoV2</kwd><kwd>Hippo pathway</kwd><kwd>YAP</kwd><kwd>TEAD</kwd><kwd>NSP13</kwd><kwd>Hela</kwd><kwd>cardiomyocytes</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL127717</award-id><principal-award-recipient><name><surname>Martin</surname><given-names>James F</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL130804</award-id><principal-award-recipient><name><surname>Martin</surname><given-names>James F</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>HL118761</award-id><principal-award-recipient><name><surname>Martin</surname><given-names>James F</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>903411</award-id><principal-award-recipient><name><surname>Meng</surname><given-names>Fansen</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id>903651</award-id><principal-award-recipient><name><surname>Li</surname><given-names>Rich G</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000050</institution-id><institution>National Heart, Lung, and Blood Institute</institution></institution-wrap></funding-source><award-id>K99 HL169742</award-id><principal-award-recipient><name><surname>Steimle</surname><given-names>Jeffrey D</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000968</institution-id><institution>American Heart Association</institution></institution-wrap></funding-source><award-id award-id-type="doi">10.58275/AHA.24CDA1274610.pc.gr.193655</award-id><principal-award-recipient><name><surname>Meng</surname><given-names>Fansen</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A novel YAP/TEAD regulatory mechanism by NSP13 provides molecular insights into Hippo-YAP regulation after SARS-CoV-2 infection.</meta-value></custom-meta><custom-meta specific-use="meta-only"><meta-name>publishing-route</meta-name><meta-value>prc</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The evolutionarily conserved Hippo-YAP signaling pathway integrates various extracellular signals, including mechanical force, cell adhesion, and nutrient availability, through the protein kinases LATS1/2 (<xref ref-type="bibr" rid="bib19">Ma et al., 2019</xref>). YAP is the primary substrate of LATS kinases, and following phosphorylation, is inactivated via cytoplasmic retention or degradation. Unphosphorylated YAP translocates to the nucleus and complexes with transcription factor partners, notably TEAD, to activate target genes (<xref ref-type="bibr" rid="bib19">Ma et al., 2019</xref>; <xref ref-type="bibr" rid="bib38">Wang et al., 2018</xref>) involved in tissue development, homeostasis, and regeneration across multiple organs (<xref ref-type="bibr" rid="bib38">Wang et al., 2018</xref>; <xref ref-type="bibr" rid="bib24">Meng et al., 2022</xref>; <xref ref-type="bibr" rid="bib36">Russell and Camargo, 2022</xref>; <xref ref-type="bibr" rid="bib9">Hong et al., 2016</xref>; <xref ref-type="bibr" rid="bib26">Moya and Halder, 2019</xref>; <xref ref-type="bibr" rid="bib46">Zhang et al., 2018</xref>). YAP/TEAD is regulated by intricate molecular mechanisms that govern its activity, localization, and interaction. Dysregulation of these processes has been implicated in various diseases, including cancer (<xref ref-type="bibr" rid="bib30">Paul et al., 2022</xref>; <xref ref-type="bibr" rid="bib35">Pocaterra et al., 2020</xref>; <xref ref-type="bibr" rid="bib16">Lin et al., 2017</xref>; <xref ref-type="bibr" rid="bib10">Huh et al., 2019</xref>).</p><p>Recent studies reveal that YAP is an endogenous brake of innate antiviral immunity (<xref ref-type="bibr" rid="bib37">Wang et al., 2017</xref>; <xref ref-type="bibr" rid="bib45">Zhang et al., 2017</xref>). Genetic loss of YAP enhances antiviral responses, whereas expression of a transactivation-deficient mutant (YAP-6SA) suppresses these responses. Conversely, multiple canonical YAP target genes, such as <italic>Il-6</italic>, <italic>Ccl2</italic>, and <italic>Csf1</italic>, modulate innate-immune signaling and cytokine production (<xref ref-type="bibr" rid="bib22">Meli et al., 2023</xref>; <xref ref-type="bibr" rid="bib40">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Xiao et al., 2019</xref>). Notably, different types of viral infection distinctly influence YAP expression, degradation, and nuclear localization (<xref ref-type="bibr" rid="bib39">Wang et al., 2019</xref>). Although these observations shed light on the complex dynamics of YAP during viral responses, the mechanisms underlying YAP/TEAD regulation after SARS-CoV-2 infection are poorly understood. SARS-CoV-2, the center of the COVID-19 pandemic, has well-documented effects on the respiratory, digestive, central nervous, and cardiovascular systems (<xref ref-type="bibr" rid="bib20">Ma et al., 2020</xref>; <xref ref-type="bibr" rid="bib3">De Felice et al., 2020</xref>; <xref ref-type="bibr" rid="bib29">Nishiga et al., 2020</xref>). Investigating SARS-CoV-2 and Hippo-YAP signaling provides molecular insight into virus-induced pathophysiology. Two groups recently reported opposite effects on YAP activity after SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib5">Garcia et al., 2022</xref>; <xref ref-type="bibr" rid="bib33">Pinto et al., 2023</xref>). However, the lack of YAP/TEAD target gene expression data in these studies prevents a full understanding of these disparate results. Thus, the precise understanding of YAP/TEAD regulation after SARS-CoV-2 infection remains elusive.</p><p>Here, we found that SARS-CoV-2 infection reduces YAP target gene expression in human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) and lung epithelial cells of COVID-19 patients. By comprehensively screening SARS-CoV-2 nonstructural proteins, we identified NSP13 as a key factor in inhibiting YAP transcriptional activity and suppressing active YAP5SA activity <italic>in vivo</italic>. Moreover, NSP13 suppression of YAP is dependent on its helicase activity, where both DNA binding and unwinding are required. Mechanistically, NSP13 is directly bound to TEAD4 and inhibits the transcriptional activity of the YAP/TEAD4 complex by remodeling chromatin and recruiting transcriptional suppressors such as TTF2. These findings reveal a novel function of NSP13 in regulating YAP/TEAD activity and provide key insights into how the SARS-CoV-2 genome modulates transcriptional activity of the YAP-TEAD complex.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>SARS-CoV-2 infection suppresses YAP activity in host cells</title><p>To assess YAP activity following SARS-CoV-2 infection <italic>in vitro</italic>, we evaluated a bulk RNA-sequencing dataset derived from hiPSC-CMs exposed to varying SARS-CoV-2 concentrations (<xref ref-type="bibr" rid="bib32">Perez-Bermejo et al., 2021</xref>; <xref ref-type="fig" rid="fig1">Figure 1A</xref>). Cardiomyocyte-specific YAP target gene (<xref ref-type="bibr" rid="bib25">Monroe et al., 2019</xref>) expression revealed that YAP targets were decreased in a dose-dependent manner after SARS-CoV-2 infection (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). YAP is known to directly regulate several innate-immunity genes in mouse, including <italic>Ccl2</italic>, <italic>Thbs1</italic>, and <italic>Csf1</italic> (<xref ref-type="bibr" rid="bib40">Wang et al., 2020</xref>; <xref ref-type="bibr" rid="bib41">Xiao et al., 2019</xref>). We observed that these genes are downregulated in SARS-CoV-2-infected cells, mirroring the decrease in canonical YAP targets such as <italic>VGLL3</italic>, <italic>AMOTL2</italic>, and <italic>CCN1</italic> (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>SARS-CoV-2 infection suppresses YAP activity.</title><p>(<bold>A</bold>) Overview of SARS-CoV-2 infection in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs). (<bold>B</bold>) Box plot showing the mean expression scores of known YAP target genes in hiPSC-CM bulk RNA-sequencing data. Each dot represents a biological replicate. Studentâs <italic>t-</italic>test; **p&lt;0.01, ****p&lt;0.0001. (<bold>C</bold>) Heatmap displaying the expression Z-scores of example YAP targets in the iPSC-CM bulk RNA-sequencing data. Each column corresponds to a single biological sample. (<bold>D</bold>) Overview of integrated single-nucleus RNA sequencing and uniform manifold approximation and projection (UMAP) of cell types in lung samples from controls and patients with COVID-19. EC, endothelial cells; NK, natural killer cells; SMC, smooth muscle cells. (<bold>E</bold>) UMAP visualization of TMPRESS2 expression in the 10 cell types. (<bold>F</bold>) GO analysis of downregulated genes in AT1 cells from COVID patients. (<bold>G</bold>) Yap scores in alveolar type 1 (AT1) and alveolar type 2 (AT2) epithelial cells from lung samples in controls and patients with COVID-19. Wilcoxon test, ****p&lt;0.0001. (<bold>H</bold>) Expression of Yap targets in AT1 and AT2 cells of control and COVID-positive lung samples.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 1.</label><caption><title>Heatmap showing the most highly expressed markers for each cell type in human lung samples.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig1-figsupp1-v1.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 2.</label><caption><title>Uniform manifold approximation and projection (UMAP) visualization showing ACE2 expression in all cell types.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig1-figsupp2-v1.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 3.</label><caption><title>Epithelial cell subtypes AT1 and AT2 with marker genes.</title><p>(<bold>A</bold>) UMAP of epithelial cell subclusters. (<bold>B</bold>) Dot plot showing the relative expression of alveolar type 1 (AT1) and alveolar type 2 (AT2) markers in human lung samples.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig1-figsupp3-v1.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1âfigure supplement 4.</label><caption><title>Expression of Yap targets genes involved in innate immune response or regulation in AT1 and AT2 cells from control and COVID-positive lung samples.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig1-figsupp4-v1.tif"/></fig></fig-group><p>We then assessed YAP activity with SARS-CoV-2 infection <italic>in vivo</italic> by integrating and reanalyzing single-nuclei RNA (snRNA) sequencing data derived from human lung samples (<xref ref-type="bibr" rid="bib4">Delorey et al., 2021</xref>; <xref ref-type="bibr" rid="bib23">Melms et al., 2021</xref>). We identified 10 major cell types (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1âfigure supplement 1</xref>). <italic>TMPRSS2</italic> and <italic>ACE2</italic>, two key entry factors for SARS-CoV-2 infection (<xref ref-type="bibr" rid="bib8">Hoffmann et al., 2020</xref>), were more highly expressed in lung epithelial cells compared to other cell types (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1s2">Figure 1âfigure supplement 2</xref>). Lung epithelial cells were categorized into alveolar type 1 (AT1) and alveolar type 2 (AT2) (<xref ref-type="fig" rid="fig1s3">Figure 1âfigure supplement 3</xref>). SARS-CoV-2 is more likely to infect AT1 cells as they cover &gt;95% of the alveolar surface. We performed an unbiased GO analysis of the differentially expressed genes (DEGs) and observed that genes associated with or regulating the Hippo pathway were downregulated in AT1 cells from COVID-19 patients (<xref ref-type="fig" rid="fig1">Figure 1F</xref>). Consistent with previous data <italic>in vitro</italic>, the YAP score, evaluated via YAP target gene expression, was lower in AT1 cells from COVID-19 patients than in controls (<xref ref-type="fig" rid="fig1">Figure 1G</xref>). Signature genes associated with AT1 cells, including the reported YAP target genes <italic>AGER</italic> and <italic>CLIC5</italic> (<xref ref-type="bibr" rid="bib31">Penkala et al., 2021</xref>; <xref ref-type="bibr" rid="bib6">Gokey et al., 2021</xref>), were downregulated in COVID-19 patient lung samples (<xref ref-type="fig" rid="fig1">Figure 1H</xref>). These data support the notion that SARS-CoV-2 infection suppresses YAP activity in host cells. However, further analysis revealed that multiple YAP target genes involved in innate immunity and cytokine signaling were paradoxically elevated (<xref ref-type="fig" rid="fig1s4">Figure 1âfigure supplement 4</xref>). This discrepancy likely reflects a combination of factors, including cell-type specificity, activation of parallel signaling pathways, and alterations in mechanical cues or tissue architecture that can independently drive expression of these genes.</p></sec><sec id="s2-2"><title>NSP13 inhibits YAP5SA transactivation</title><p>To identify which SARS-CoV-2 protein suppresses YAP activity, we screened 11 NSP proteins using a dual-luciferase reporter assay. This assay measures firefly and Renilla luciferase activities sequentially from the same sample. Normalization to Renilla luciferase serves as an internal control, ensuring accuracy and reproducibility of the results. Compared with other NSPs, NSP13 strongly inhibited YAP transcription activity (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). By using a constitutively active form of YAP (YAP5SA) that is resistant to phosphorylation and inactivation by LATS1/2 (<xref ref-type="bibr" rid="bib47">Zhao et al., 2007</xref>), we observed that NSP13 suppresses YAP transactivation independent of its upstream kinase LATS2 (<xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>). Moreover, NSP13 attenuated YAP5SA activity dose-dependently (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). A recent study reported that NSP13 suppresses episomal DNA transcription, as evidenced by reduced Renilla luciferase activity and decreased GFP expression upon co-expression with NSP13 (<xref ref-type="bibr" rid="bib15">Li et al., 2023</xref>). To evaluate this in our system, we examined our raw Renilla luciferase data and found that while 100 â¯ng of NSP13 had no effect, 400 â¯ng of NSP13 reduced Renilla luciferase levels by approximately 50% compared to the YAP5SA-only group (<xref ref-type="fig" rid="fig2s2">Figure 2âfigure supplement 2</xref>). Notably, the firefly luciferase signal, driven by YAP/TEAD interaction (HOP-Flash), exhibited an even greater reduction. To assess the specificity of this suppression, we also conducted a Notch reporter assay and observed that co-expression of NSP13 with NICD (Notch intracellular domain) did not inhibit Notch signaling (<xref ref-type="fig" rid="fig2s3">Figure 2âfigure supplement 3</xref>). These results reveal a specific suppressive effect of NSP13 on YAP-mediated transcriptional activity.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>NSP13 inhibits YAP transactivation.</title><p>(<bold>A</bold>) Screening of 11 NSPs for YAP activation by using a dual-luciferase reporter assay (HOP-flash). Compared with other NSPs, NSP13 strongly inhibited YAP transactivation at low protein expression levels. (n=3 independent experiments; data are reported as mean Â± SD). ****p&lt;0.0001, one-way ANOVA. (<bold>B</bold>) Reporter assay (8xGTIIC) results showing that NSP13 but not YAP upstream kinase LATS2 inhibited YAP5SA transactivation in a dose-dependent manner. (n=3 independent experiments; data are presented as the mean Â± SD). ***p&lt;0.001, ****p&lt;0.0001, one-way ANOVA. (<bold>C</bold>) Experimental design of NSP13 study in mice. Control (aMyHC-MerCreMer;WT) and YAP5SA (aMyHC-MerCreMer;YAP 5SA) mice were injected with AAV9-GFP or AAV9-NSP13. At 12 days after virus injection, the mice received two low doses of TAM (10 ug/g). Cardiac function was recorded by echocardiography at days 4 and 8 after the second shot of tamoxifen. Hearts of all surviving mice were collected at day 21 post-tamoxifen injection. (<bold>D</bold>) NSP13 expression in cardiomyocytes improved the survival rate of YAP5SA mice after TAM injection compared to YAP5SA mice with AAV9-GFP infection. **p=0.0099, log-rank (MantelâCox) test. (<bold>E</bold>) Ejection fraction in YAP5SA mice was increased on day 8 after tamoxifen injections (10 ug/g x2). NSP13 expression reversed the increase of EF in YAP5SA mice. (n=6 in MCM + GFP, MCM + NSP13, and YAP5SA + GFP group; n=8 in YAP5SA + NSP13 group). ****p&lt;0.0001, three-way ANOVA. (<bold>F</bold>) Representative B-mode and M-mode echocardiographic images of mouse hearts in four groups, 8 days after tamoxifen (TAM) induction. (<bold>G</bold>) A reduction in the left ventricle size was seen in YAP5SA mice at day 8 after tamoxifen injection. NSP13 introduction reversed this trend as evidenced by an increase in the diameter of the left ventricle (n=6 in MCM + GFP, MCM + NSP13, and YAP5SA + GFP group; n=8 in YAP5SA + NSP13 group). ***p&lt;0.001, three-way ANOVA. (<bold>H, I</bold>) Representative whole mount and H&amp;E images of mouse hearts at 21 days after tamoxifen induction. Scale bar, 2 mm.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2">Figure 2A</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata2"><label>Figure 2âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2">Figure 2A</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata3"><label>Figure 2âsource data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2">Figure 2B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2sdata4"><label>Figure 2âsource data 4.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2">Figure 2B</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-data4-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 1.</label><caption><title>Reporter assay (HOP-flash) results indicating that NSP13 inhibited YAP5SA transactivation at low protein expression levels when compared with other NSPs.</title><p>n=3 independent experiments; data are presented as mean Â± SD. ****p&lt;0.0001, one-way ANOVA.</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2âfigure supplement 1âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s1sdata2"><label>Figure 2âfigure supplement 1âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s1">Figure 2âfigure supplement 1</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig2-figsupp1-v1.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 2.</label><caption><title>Raw reads of Renilla luciferase in <xref ref-type="fig" rid="fig2">Figures 2A</xref> and <xref ref-type="fig" rid="fig3">3B and D</xref>.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig2-figsupp2-v1.tif"/></fig><fig id="fig2s3" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 3.</label><caption><title>Reporter assay (Notch reporter) results showing that NSP13 cannot suppress NICD activation.</title><p>n=3 independent experiments; data are presented as mean Â± SD.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig2-figsupp3-v1.tif"/></fig><fig id="fig2s4" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 4.</label><caption><title>NSP13 expression at different time points in mouse hearts after AAV9-HA-NSP13 virus injection.</title><p><supplementary-material id="fig2s4sdata1"><label>Figure 2âfigure supplement 4âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig2s4">Figure 2âfigure supplement 4</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-figsupp4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig2s4sdata2"><label>Figure 2âfigure supplement 4âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig2s4">Figure 2âfigure supplement 4</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig2-figsupp4-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig2-figsupp4-v1.tif"/></fig><fig id="fig2s5" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 5.</label><caption><title>Fractional shortening was increased in YAP5SA mice at day 8 after tamoxifen injection (10 ug/g x2).</title><p>This increase was reversed by NSP13 expression. (n=6 in MCM + GFP, MCM + NSP13, and YAP5SA + GFP group; n=8 in YAP5SA + NSP13 group). ****p&lt;0.0001, three-way ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig2-figsupp5-v1.tif"/></fig><fig id="fig2s6" position="float" specific-use="child-fig"><label>Figure 2âfigure supplement 6.</label><caption><title>The overgrowth of the heart in YAP5SA mice, as evidenced by heart/body ratio, was reversed by NSP13 expression.</title><p>n=6 in MCM + GFP and MCM + NSP13 group; n=4 in YAP5SA + GFP group; n=8 in YAP5SA + NSP13 group. *p=0.0175, one-way ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig2-figsupp6-v1.tif"/></fig></fig-group><p>To investigate NSP13 function <italic>in vivo</italic>, we used YAP5SA transgenic mice (aMyHC-MerCreMer;YAP5SA), which express YAP5SA in cardiomyocytes following tamoxifen administration. YAP5SA induction produces cardiomyocyte hyperplasia and increased ejection fraction (EF) and fractional shortening (FS), ultimately leading to mortality (<xref ref-type="bibr" rid="bib25">Monroe et al., 2019</xref>). We used the adenovirus expressing NSP13 (AAV9-NSP13), which specifically infects cardiomyocytes (<xref ref-type="fig" rid="fig2s4">Figure 2âfigure supplement 4</xref>, <xref ref-type="fig" rid="fig2">Figure 2C</xref>). NSP13-induced expression in YAP5SA mouse cardiomyocytes increased survival rates (<xref ref-type="fig" rid="fig2">Figure 2D</xref>) and restored cardiac function (<xref ref-type="fig" rid="fig2">Figure 2E</xref>, <xref ref-type="fig" rid="fig2s5">Figure 2âfigure supplement 5</xref>). Furthermore, NSP13 expression reversed the smaller left ventricle (LV) chamber in YAP5SA mouse hearts (<xref ref-type="bibr" rid="bib25">Monroe et al., 2019</xref>; <xref ref-type="fig" rid="fig2">Figure 2F and G</xref>). To investigate NSP13 induction in the mouse heart further, we collected heart tissue from surviving mice 21 days after tamoxifen injection. Notably, NSP13 expression in YAP5SA mice reversed heart overgrowth (<xref ref-type="fig" rid="fig2">Figure 2H and I</xref>, <xref ref-type="fig" rid="fig2s6">Figure 2âfigure supplement 6</xref>). Together, these data indicate that NSP13 suppresses YAP activity <italic>in vitro</italic> and <italic>in vivo</italic>.</p></sec><sec id="s2-3"><title>NSP13 helicase activity is required for YAP suppression</title><p>NSP13, a helicase with conserved sequence across all coronaviruses (<xref ref-type="fig" rid="fig3">Figure 3A</xref>), plays a critical role in viral replication and is a promising target for antiviral treatment (<xref ref-type="bibr" rid="bib43">Yan et al., 2021</xref>; <xref ref-type="bibr" rid="bib1">Chen et al., 2020</xref>; <xref ref-type="bibr" rid="bib42">Yan et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Newman et al., 2021</xref>; <xref ref-type="bibr" rid="bib2">Chen et al., 2022</xref>; <xref ref-type="bibr" rid="bib21">Malone et al., 2021</xref>; <xref ref-type="bibr" rid="bib27">Nandi et al., 2022</xref>; <xref ref-type="bibr" rid="bib44">Zeng et al., 2021</xref>). K131, K345/K347, and R567 were identified as important amino acid sites for NSP13 helicase activity in SARS-CoV (<xref ref-type="bibr" rid="bib11">Jia et al., 2019</xref>). Given the 99.8% sequence identity of NSP13 between SARS-CoV-2 and SARS-CoV, we speculated that these sites were similarly crucial for SARS-CoV-2 NSP13. Reporter assays revealed that NSP13-K131A, which retains partial helicase activity, can suppress YAP, whereas NSP13-R567A (no ATP consumption) and NSP13-K345A/K347A (obstructed nucleic acid binding channel) failed to inhibit YAP transcriptional activity (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). To assess the contribution of each domain to YAP regulation, we constructed six NSP13 truncations (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), yet none of these truncations reduced YAP transactivation (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). These findings suggest that full-length NSP13 with helicase activity (DNA binding and ATPâdependent unwinding) is required to suppress YAP transactivation, and that partial helicase function is sufficient to fully inhibit YAP.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>NSP13 helicase activity is required for suppressing YAP activity.</title><p>(<bold>A</bold>) Conserved amino acid sequences of NSP13 among coronaviruses. (<bold>B</bold>) SARS-CoV-2 NSP13 mutant plasmids were constructed to examine YAP suppression mechanisms. NSP13-R567A, which loses its ATP consumption ability, did not inhibit YAP5SA transactivation, whereas NSP13 K345A/K347A, which loses its nucleic acid binding activity, mildly promoted YAP5SA transactivation (n=3 independent experiments; data are reported as the mean Â± SD). **p&lt;0.01, ****p&lt;0.0001, one-way ANOVA. (<bold>C</bold>) Six NSP13 truncations were constructed based on the NSP13 domain map. (<bold>D</bold>) Reporter assay: none of the truncations led to a reduction in YAP transactivation, and the NSP13 DNA binding domains 1A and 2A slightly increased YAP5SA activation, suggesting that the full-length NSP13 with helicase activity may be required for suppression of YAP transactivation (n=3 independent experiments; data are reported as the mean Â± SD). *p&lt;0.05, ****p&lt;0.0001, one-way ANOVA. (<bold>E</bold>) Summary of NSP13 mutants from SARS-CoV-2 variants. (<bold>F</bold>) HOP-flash reporter assay: NSP13 mutations did not affect suppression of YAP5SA transactivation (n=3 independent experiments; data are reported as mean Â± SD). ****p&lt;0.0001, one-way ANOVA.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3">Figure 3B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata2"><label>Figure 3âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig3">Figure 3B</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig3-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata3"><label>Figure 3âsource data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3">Figure 3D</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig3-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata4"><label>Figure 3âsource data 4.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig3">Figure 3D</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig3-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata5"><label>Figure 3âsource data 5.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig3">Figure 3F</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig3-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig3sdata6"><label>Figure 3âsource data 6.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig3">Figure 3F</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig3-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3âfigure supplement 1.</label><caption><title>SARS-CoV-2 NSP13 mutations: structural locations and functional effect on YAP5SA transactivation.</title><p>(<bold>A</bold>) The location of the NSP13 mutations from SARS-CoV2 variants on the NSP13 protein structure model (PDB: 7NN0). (<bold>B</bold>) Reporter assay (8xGTIIC) results indicating that NSP13 mutations did not affect its suppression on YAP5SA transactivation (n=3 independent experiments; data are presented as mean Â± SD). ****p&lt;0.0001, one-way ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig3-figsupp1-v1.tif"/></fig></fig-group><p>SARS-CoV-2 has consistently mutated over time, resulting in variants that differ from the original virus. We evaluated NSP13 mutations (<xref ref-type="bibr" rid="bib28">Newman et al., 2021</xref>) and observed that all mutants can suppress YAP transactivation (<xref ref-type="fig" rid="fig3">Figure 3E and F</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3âfigure supplement 1</xref>).</p></sec><sec id="s2-4"><title>NSP13 interacts with TEAD4 and recruits YAP repressors</title><p>To determine the molecular mechanism(s) underlying NSP13 suppression of YAP, we performed immunofluorescence (IF) analyses. Our data revealed that NSP13 localizes to the cytoplasm and nucleus, whereas most YAP5SA colocalizes with NSP13 in the nucleus three days after tamoxifen injection (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). However, co-immunoprecipitation (co-IP) assays revealed no direct interaction between NSP13 and YAP5SA (<xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>). Additional assays indicated that NSP13 is associated with the transcription factor TEAD4 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>), and both the N- and C-terminal ends of TEAD4 interact with NSP13 (<xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2</xref>), suggesting that NSP13 prevents YAP transactivation by competitively interacting with TEAD4. Unexpectedly, introduction of NSP13 had no effect on the YAP/TEAD4 association (<xref ref-type="fig" rid="fig4s3">Figure 4âfigure supplement 3</xref>). However, the YAP/NSP13 interaction was much stronger in the presence of TEAD4, indicating that TEAD4 is a platform to recruit YAP and NSP13 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Consistent with this, IF analysis of HeLa cells and heart sections revealed that YAP5SA is restricted to the nucleus when co-expressed with either NSP13 WT or R567A, in contrast to the vector control (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, <xref ref-type="fig" rid="fig4s4">Figure 4âfigure supplement 4</xref>). Moreover, NSP13 protein levels in cardiomyocytes accumulated following YAP5SA induction (<xref ref-type="fig" rid="fig4">Figure 4D and E</xref>), suggesting that nuclear NSP13/YAP/TEAD4 prevents NSP13 degradation. Given that NSP13 preferentially interacts with TEAD4 in the nucleus (<xref ref-type="fig" rid="fig4">Figure 4B-C</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4âfigure supplement 3</xref>), we next determined whether this association was DNAâdependent using multiple nucleases: Universal Nuclease (which degrades all forms of DNA and RNA), DNaseâ¯I (which cleaves both singleâ and doubleâstranded DNA), and RNaseâ¯H (which selectively cleaves the RNA strand in RNA/DNA hybrids). These treatments did not disrupt the NSP13/TEAD4 interaction (<xref ref-type="fig" rid="fig4s5">Figure 4âfigure supplement 5</xref>), revealing that their binding is not dependent on nucleic acids.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>NSP13 inactivates the YAP/TEAD4 complex by recruiting YAP repressors.</title><p>(<bold>A</bold>) Immunofluorescence imaging showing that NSP13 colocalized with YAP5SA in cardiomyocytes of YAP5SA transgenic mice 3 days after tamoxifen injection. Scale bar, 20 Î¼m. (<bold>B</bold>) Co-IP: NSP13 interacts with TEAD4, a major binding partner of YAP, in the nucleus. (<bold>C</bold>) Co-IP of HEK293T nuclei: NSP13 does not disrupt the interaction between YAP and TEAD4, whereas TEAD4 promotes the interaction between YAP and NSP13. (<bold>D, E</bold>) Immunofluorescence imaging and western blot analysis reveal that NSP13 protein levels increase after YAP5SA expression is induced in YAP5SA mouse cardiomyocytes. Scale bar, 50 Î¼m. (<bold>F</bold>) Workflow of IP-MS. (<bold>G</bold>) IP-MS in nuclei (IP: NSP13), suggesting NSP13 interacts with proteins with or without YAP co-expression. Significance Analysis of INTeractome (SAINT), AvgP &gt;0.6 are labeled in red. (<bold>H</bold>) GO analysis in subclusters of NSP13 interacting proteins (SAINT, AvgP &gt;0.6, labeled with red in Figure S4C). (<bold>I</bold>) HOP-flash reporter assay: endogenous YAP activity is increased after the siRNA knockdown of CCT3 and TTF2 in HeLa cells (n=3 independent experiments; data are reported as mean Â± SD). ***p&lt;0.001, ****p&lt;0.0001, one-way ANOVA. (<bold>J</bold>) Working model for NSP13 regulation of YAP/TEAD.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata2"><label>Figure 4âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4B</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-data2-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata3"><label>Figure 4âsource data 3.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-data3-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata4"><label>Figure 4âsource data 4.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4C</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-data4-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata5"><label>Figure 4âsource data 5.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4">Figure 4E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-data5-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4sdata6"><label>Figure 4âsource data 6.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4">Figure 4E</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-data6-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 1.</label><caption><title>Western blot analysis showed that neither wild-type nor mutant NSP13 directly interacted with YAP5SA in HEK 293T cells.</title><p><supplementary-material id="fig4s1sdata1"><label>Figure 4âfigure supplement 1âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp1-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s1sdata2"><label>Figure 4âfigure supplement 1âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s1">Figure 4âfigure supplement 1</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 2.</label><caption><title>TEAD4 domain mapping experiments showing that both the N-terminus and C-terminus are required for the interaction with NSP13.</title><p><supplementary-material id="fig4s2sdata1"><label>Figure 4âfigure supplement 2âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp2-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s2sdata2"><label>Figure 4âfigure supplement 2âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s2">Figure 4âfigure supplement 2</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp2-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp2-v1.tif"/></fig><fig id="fig4s3" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 3.</label><caption><title>Co-immunoprecipitation in nucleus indicated that NSP13 wild-type and R567A did not disrupt YAP and TEAD4 interaction.</title><p><supplementary-material id="fig4s3sdata1"><label>Figure 4âfigure supplement 3âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s3">Figure 4âfigure supplement 3</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp3-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s3sdata2"><label>Figure 4âfigure supplement 3âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s3">Figure 4âfigure supplement 3</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp3-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp3-v1.tif"/></fig><fig id="fig4s4" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 4.</label><caption><title>Immunofluorescence imaging showing that both NSP13 WT and R567A restricted YAP5SA in cell nucleus.</title><p>Scale bar, 50 Î¼m.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp4-v1.tif"/></fig><fig id="fig4s5" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 5.</label><caption><title>Western blot analysis of co-IP showed that nucleic acid removal did not disrupt the NSP13âTEAD4 interaction.</title><p><supplementary-material id="fig4s5sdata1"><label>Figure 4âfigure supplement 5âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s5">Figure 4âfigure supplement 5</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp5-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s5sdata2"><label>Figure 4âfigure supplement 5âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s5">Figure 4âfigure supplement 5</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp5-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp5-v1.tif"/></fig><fig id="fig4s6" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 6.</label><caption><title>STRING analysis of NSP13 interacting proteins.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp6-v1.tif"/></fig><fig id="fig4s7" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 7.</label><caption><title>Co-IP assays indicated that the NSP13 interactors from mass spectrometry had weaker binding with NSP13 compared to TEAD4.</title><p><supplementary-material id="fig4s7sdata1"><label>Figure 4âfigure supplement 7âsource data 1.</label><caption><title>Original files for western blot analysis displayed in <xref ref-type="fig" rid="fig4s7">Figure 4âfigure supplement 7</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp7-data1-v1.zip"/></supplementary-material></p><p><supplementary-material id="fig4s7sdata2"><label>Figure 4âfigure supplement 7âsource data 2.</label><caption><title>Original western blots for <xref ref-type="fig" rid="fig4s7">Figure 4âfigure supplement 7</xref>, indicating the relevant bands and treatments.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-100248-fig4-figsupp7-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp7-v1.tif"/></fig><fig id="fig4s8" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 8.</label><caption><title>siRNA knockdown efficiency for genes in HeLa cells, determined by using quantitative polymerase chain reaction (n=3 independent experiments; data are presented as mean Â± SD).</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp8-v1.tif"/></fig><fig id="fig4s9" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 9.</label><caption><title>Reporter assay (8xGTIIC) results in HeLa cells revealed that endogenous YAP activity was increased after the siRNA-mediated knockdown of CCT3 and TTF2.</title><p>n=3 independent experiments; data are presented as mean Â± SD. ****p&lt;0.0001, one-way ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp9-v1.tif"/></fig><fig id="fig4s10" position="float" specific-use="child-fig"><label>Figure 4âfigure supplement 10.</label><caption><title>Quantitative PCR analysis indicated increased expression of <italic>CTGF</italic> and <italic>CYR61</italic> following <italic>CCT3</italic> knockdown.</title><p>Data are presented as mean Â± SD (n=3). *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, two-way ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-100248-fig4-figsupp10-v1.tif"/></fig></fig-group><p>Given that NSP13 forms a complex with YAP and TEAD4 (<xref ref-type="fig" rid="fig4">Figure 4C</xref>, <xref ref-type="fig" rid="fig4s3">Figure 4âfigure supplement 3</xref>), we hypothesized that it recruits nuclear repressors to inhibit YAP transactivation. To investigate this, we performed immunoprecipitation followed by mass spectrometry (IP-MS) to identify NSP13-interacting proteins in the presence or absence of YAP in HEK293T cell nuclei (<xref ref-type="fig" rid="fig4">Figure 4F</xref> and <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>). Our analyses identified hundreds of candidate proteins that interact with NSP13 in the nucleus (<xref ref-type="fig" rid="fig4">Figure 4G</xref> and <xref ref-type="supplementary-material" rid="sdata2">Source data 2</xref>), which were further analyzed by STRING-based network analysis (<xref ref-type="fig" rid="fig4s6">Figure 4âfigure supplement 6</xref> and <xref ref-type="supplementary-material" rid="sdata3">Source data 3</xref>). Gene Ontology (GO) analysis indicated that the largest clusters are involved in RNA polymerase II transcription termination, chromatin remodeling, and protein folding (<xref ref-type="fig" rid="fig4">Figure 4H</xref>). To validate these candidate interactors, we evaluated several proteinsâCCT3, SMARCD1, EIF4A1, LMNA, TTF2, and YY2âand conducted co-IP assays. Whereas TEAD4 strongly interacts with NSP13 (<xref ref-type="fig" rid="fig4s7">Figure 4âfigure supplement 7</xref>), the candidate repressors exhibited relatively weak binding to NSP13, suggesting that NSP13 associates with these proteins indirectly, potentially through a larger multiprotein complex or via chromatin-dependent interactions (<xref ref-type="fig" rid="fig4">Figure 4J</xref>).</p><p>Next, we evaluated the functional consequence of siRNA knockdown of selected candidates in YAP transactivation (<xref ref-type="fig" rid="fig4s8">Figure 4âfigure supplement 8</xref>). Reporter assays revealed that knockdown of CCT3 and TTF2 increased endogenous YAP transactivation in HeLa cells (<xref ref-type="fig" rid="fig4">Figure 4I</xref>, <xref ref-type="fig" rid="fig4s9">Figure 4âfigure supplement 9</xref>). To confirm the function of CCT3, we performed quantitative PCR analysis of classical YAP target genes and observed increased expression of <italic>CTGF</italic> and <italic>CYR61</italic> following <italic>CCT3</italic> knockdown (<xref ref-type="fig" rid="fig4s10">Figure 4âfigure supplement 10</xref>). These findings support a model where NSP13 suppresses YAP activity by recruiting suppressors to the YAP/TEAD4 complex.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>In this study, we observed that SARS-CoV-2 infection in human lung and hiPSC-CMs reduces YAP transcriptional activity, wherein the SARS-CoV-2 helicase NSP13 significantly inhibited YAP activity. Mechanistically, NSP13 directly interacts with TEAD4 to form a YAP/TEAD4/NSP13 complex in the nucleus, which recruits suppressors such as TTF2 and CCT3 to repress YAP-TEAD transcriptional activity (<xref ref-type="fig" rid="fig4">Figure 4J</xref>).</p><p>Our data reveal a helicaseâdependent inhibition of YAP by NSP13, where the K131, K345/K347, and R567 NSP13 residues are required. Based on published structural and biochemical studies, each of these residues uniquely supports helicase function: Substituting K131 with alanine (K131A) severely reduces helicase efficiency; K345/K347 are key DNAâbinding residues as mutating both (K345A/K347A) abolishes DNA binding; mutation of the ATP hydrolysis residue R567 (R567A) disables DNA unwinding. As illustrated in <xref ref-type="fig" rid="fig4">Figure 4J</xref>, NSP13 must bind DNA and hydrolyze ATP to unwind nucleic acids. This helicaseâdependent process likely enables NSP13 to remodel chromatin by binding TEAD and organizing YAP repressors at the YAP/TEAD complex to prevent YAP/TEAD transactivation. In support of this mechanism, the K345A/K347A mutant, unable to anchor to DNA, fails to repress YAP as YAPâdriven transcription is slightly increased in this mutant (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Likewise, the ATPaseâdead R567A can bind DNA but does not unwind and remodel chromatin to recruit YAP repressors, resulting in a loss of YAP suppression (<xref ref-type="fig" rid="fig3">Figure 3B and F</xref>). Our model demonstrates that both DNA binding and ATPâdependent unwinding are essential for NSP13 to suppress YAP transcriptional activity.</p><p>TEAD transcription factors, the major partners of YAP, are the primary nuclear effectors of Hippo-YAP signaling and play critical roles in cancer development (<xref ref-type="bibr" rid="bib10">Huh et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Pobbati et al., 2023</xref>). We observed that NSP13 interacts with TEAD4, but does not disrupt the YAP/TEAD4 interaction, suggesting a novel regulatory mechanism for TEAD. IP-MS revealed that NSP13-interacting proteins such as TTF2 and CCT3 suppress the YAP-TEAD4 complex. TTF2, an SWI2/SNF2 family member, facilitates the removal of RNA polymerase II from the DNA template via ATP hydrolysis (<xref ref-type="bibr" rid="bib17">Liu et al., 1998</xref>; <xref ref-type="bibr" rid="bib12">Jiang et al., 2004</xref>). Importantly, termination of transcription complex elongation by TTF2 appears minimally affected by template position (<xref ref-type="bibr" rid="bib12">Jiang et al., 2004</xref>). CCT3 is a component of the chaperonin-containing T-complex, a molecular chaperone complex that promotes protein folding following ATP hydrolysis. Previous reports revealed that the liver cancer biomarker CCT3 (<xref ref-type="bibr" rid="bib18">Liu et al., 2019</xref>) positively regulates YAP protein stability. We found that CCT3 interacts with NSP13 and inhibits YAP transactivation. Moreover, CCT3 knockdown increases YAP target gene expression, suggesting a context-dependent role of CCT3 in YAP regulation. While Co-IP assays detected weak interactions between NSP13 and CCT3 or TTF2, a strong NSP13/TEAD4 interaction was evident. These data suggest that NSP13 associates with CCT3 and TTF2 indirectly as part of a multiprotein complex in a chromatin structure-dependent manner, although further study is required to elucidate these mechanisms.</p><p>In conclusion, our study reveals a novel function of NSP13 in suppressing the YAP/TEAD transcriptional complex. These findings advance our understanding of the pathological effects of SARS-CoV-2 on host cells. Given that NSP13 directly interacts with TEAD4 and strongly suppresses YAP transactivation, this work provides a new avenue for modulating YAP activity as a potential treatment for YAP-driven diseases.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Mice</title><p>Mouse studies were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and with approval from the Institutional Animal Care and Use Committee at Baylor College of Medicine. We used Î±MyHC-MerCreMer mice (The Jackson Laboratory, strain #005657, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:005657">IMSR_JAX:005657</ext-link>), wild-type (WT) mice (The Jackson Laboratory, strain #000664, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:IMSR_JAX:000664">IMSR_JAX: 000664</ext-link>), and Î±MyHC-MerCreMer; YAP5SA mice (a mixed genetic background of C57BL/6 and 129SV) in this study. The YAP5SA transgenic mice were constructed by Martin lab (<xref ref-type="bibr" rid="bib25">Monroe et al., 2019</xref>). Animals were assigned to experimental groups using simple randomization. The AAV9 virus (a total of 5âÃâ10<sup>11</sup> viral genomes, 120âÎ¼l total volume) was delivered by retro-orbital injection 2 weeks before tamoxifen injection. For the survival experiment in <xref ref-type="fig" rid="fig2">Figure 2</xref>, two low doses of tamoxifen (10 Î¼g/g) were administered to 6-week-old mice by intraperitoneal injection. The mouse cardiac function was evaluated by echocardiography at days 4 and 8 post-tamoxifen injection, and all the surviving mice were sacrificed at day 21. For the experiments in <xref ref-type="fig" rid="fig4">Figure 4</xref>, two tamoxifen doses were injected (<xref ref-type="fig" rid="fig4">Figure 4A</xref> 10 Î¼g/g; <xref ref-type="fig" rid="fig4">Figure 4D and E</xref> 50 Î¼g/g), and mouse hearts were collected at day 3 post-tamoxifen injection. The influence of sex was analyzed as a source of variation. For all mouse studies, we examined equal numbers of male and female animals, and similar findings are reported for both sexes. All analyses in mice were performed blinded.</p></sec><sec id="s4-2"><title>RNA-seq analysis</title><p>To analyze lung samples from COVID-19 patients, snRNA sequencing data of 7 control lungs and 35 COVID-19 lungs from GSE171668 (<xref ref-type="bibr" rid="bib4">Delorey et al., 2021</xref>) and GSE171524 (<xref ref-type="bibr" rid="bib23">Melms et al., 2021</xref>) were downloaded and analyzed using the Seurat v4 software suite (<xref ref-type="bibr" rid="bib7">Hao et al., 2021</xref>). A total of 223,106 nuclei were used in the analysis. Each sample was normalized and batch corrected using SCTransformation. Mitochondrial percentage was used to regress out technical variability between batches, and we used harmony (<xref ref-type="bibr" rid="bib13">Korsunsky et al., 2019</xref>) integration to remove technical variation among samples. The YAP score was evaluated using 38 canonical YAP target genes. For analyzing iPSC-CMs infected with SARS-CoV-2, bulk RNA-seq data were obtained from <xref ref-type="bibr" rid="bib32">Perez-Bermejo et al., 2021</xref>. With this dataset, we reanalyzed and evaluated the average expression of 302 cardiomyocyte-specific YAP target genes (<xref ref-type="bibr" rid="bib25">Monroe et al., 2019</xref>).</p></sec><sec id="s4-3"><title>Expression plasmids</title><p>Expression plasmids encoding HA-tagged WT, mutant, or truncated NSP13 were generated by polymerase chain reaction (PCR) and subcloned into pXF4H (N-terminal HA tag) derived from pRK5 (Genetech). Myc-tagged WT or truncated TEAD4, flag-tagged WT YAP, flag-tagged YAP5SA, and Myc-tagged NSP13 interacting proteins, including CCT3, SMARCD1, EIF4A1, LMNA, TTF2, and YY2, were generated by PCR and subcloned into a pcDNA3 backbone. HA-tagged WT LATS2, LATS2 KR, and pRL-TK_Luc were gifts from Dr. Pinglong Xuâs lab. Reporters of HOP-flash (#83467) and 8xGTIIC-luciferase (#34615) were purchased from Addgene. The NSP plasmids used in YAP transactivation screening experiments were gifts from Dr. Nevan J. Kroganâs lab. All plasmids were confirmed by performing DNA sequencing.</p></sec><sec id="s4-4"><title>Cell culture and transfection</title><p>HEK293T and HeLa cells were cultured in Dulbeccoâs Modified Eagle Medium with 10% fetal bovine serum. Lipofectamine 2000 (Thermo Fisher) or Lipofectamine 3000 (Thermo Fisher) reagents were used for plasmid transfection. LipofectAmine RNAiMAX (Thermo Fisher) was used for siRNA transfection. Both cell lines were obtained from the American Type Culture Collection (ATCC, HEK293T CRL-3216, HeLa CCL-2). The identity of the cell lines was authenticated by short tandem repeat (STR) profiling, and all cell lines tested negative for mycoplasma contamination using PCR-based assays. HeLa cells are included on the list of commonly misidentified cell lines maintained by the International Cell Line Authentication Committee (ICLAC). However, their use in this study was intentional and appropriate for the experimental design. The specific characteristics of HeLa cells were required for our assays, and their identity and relevance to the research objectives were confirmed through STR profiling and functional validation.</p></sec><sec id="s4-5"><title>Immunoprecipitation-mass spectrometry, database search, and data analysis</title><p>HEK293T cells were plated on a 150 mm tissue culture dish using 10% FBS DMEM 24 h post-plating. Cells were transfected with Flag-YAP1, HA-NSP13, or Flag-YAP1 + HA-NSP13 by Lipofectamine 3000 using standard manufacturerâs protocols. Each experimental group was performed in duplicate to ensure reproducibility and reliability. 24 h post-transfection, cells were collected in a hypotonic lysis buffer (5 mM NaCl, 20 mM HEPES, pH 7.5, 0.4% NP-40) supplemented with protease inhibitor (Roche) and phosphatase inhibitor (Roche). Cell suspensions were drawn into a 3 ml syringe using a 25 G needle and expelled in one rapid stroke into a new tube. After three rounds of lysis, the suspension was centrifuged at 600 Ã <italic>g</italic> 4Â°C for 10 min to pellet nuclei. The supernatant was collected in a different tube, and the nuclear fraction was washed in the buffer twice. After the final wash, nuclei were resuspended in 20 mM HEPES, 150 mM NaCl, 2.5 mM MgCl<sub>2</sub>, 0.1% NP 40, and nuclear fractions were sonicated using Bioruptor Pico for 10 cycles of 30 s on and 30 s off. Subsequently, lysate was centrifuged for 20 min at 2 Ã 1000 <italic>g</italic> at 4Â°C. The supernatant was incubated with HA magnetic beads (Thermo Fisher) for 2 h at 4Â°C with continuous rotation. Antibody and protein-bound beads were washed thrice for 15 min in lysis buffer at 4Â°C with constant rotation. Washed beads were boiled in 40 Î¼l of 1X NUPAGE LDS sample buffer (Invitrogen) and subjected to SDS-PAGE (NuPAGE 10% Bis-Tris Gel, Invitrogen). Eluted proteins were visualized with Coomassie Brilliant blue stain and excised into gel pieces according to molecular size. Individual gel pieces were destained and subjected to in-gel digestion using trypsin (GenDepot T9600). Tryptic peptides were resuspended in 10 Î¼l of loading solution (5% methanol containing 0.1% formic acid) and subjected to nanoflow LC-MS/MS analysis with a nano-LC 1000 system (Thermo Scientific) coupled to Orbitrap Elite (Thermo Scientific) mass spectrometer. Peptides were loaded onto a Reprosil-Pur Basic C18 (1.9 Âµm, Dr. Maisch GmbH, Germany) precolumn of 2 cm Ã 100 Âµm size. The precolumn was switched in-line with an in-house 50 mm Ã 150 Âµm analytical column packed with Reprosil-Pur Basic C18 equilibrated in 0.1% formic acid/water. Peptides were eluted using a 75 min discontinuous gradient of 4â26% acetonitrile/0.1% formic acid at a 700 nl/min flow rate. Eluted peptides were directly electro-sprayed into Orbitrap Elite mass spectrometer operated in the data-dependent acquisition mode acquiring fragmentation spectra of the top 25 strongest ions and under the direct control of Xcalibur software (Thermo Scientific).</p><p>MS/MS spectra were analyzed using the target-decoy mouse RefSeq database in the Proteome Discoverer 1.4 interface (Thermo Fisher), employing the Mascot algorithm (Mascot 2.4, Matrix Science). The precursor mass tolerance was set to 20 ppm, with a fragment mass tolerance of 0.5 daltons and a maximum of two allowed missed cleavages. Dynamic modifications included oxidation, protein N-terminal acetylation, and destreaking. Peptides identified from the Mascot results were validated at a 5% false discovery rate, and the iBAQ algorithm was applied to assess protein abundance, enabling comparisons of relative quantities among different proteins in the sample. The iBAQ value was determined by normalizing the summed peptide intensity by the number of theoretically observable tryptic peptides for each protein. PSM values from Proteome Discover were uploaded to the SAINT user interface on the CRAPOME website for SAINT analysis. SAINT probability and fold change were calculated using YAP IP as a user-defined control.</p></sec><sec id="s4-6"><title>Luciferase reporter assay</title><p>HEK293T or HeLa cells were transfected with WT YAP- or YAP5SA-responsive HOP-flash plasmid or 8xGTIIC-luciferase reporter, which has an open-reading frame encoding firefly luciferase, along with the pRL-Luc with <italic>Renilla</italic> luciferase coding as the internal control for transfection and other expression vectors (NSPs), as specified. After 24 h of transfection with the indicated treatments, cells were lysed with passive lysis buffer (Promega). Luciferase assays were performed by using a dual-luciferase assay kit (Promega), and data were quantified with POLARstar Omega (BMG Labtech) and normalized to the internal <italic>Renilla</italic> luciferase control.</p></sec><sec id="s4-7"><title>AAV9 viral packaging</title><p>Viral vectors were used as previously described (<xref ref-type="bibr" rid="bib14">Leach et al., 2017</xref>). The construct containing HA-tagged NSP13 was cloned into the pENN.AAV.cTNT, p1967-Q vector (AAV9-HA-NSP13). Empty vector-encoding green fluorescent protein was used as the control (AAV9-GFP). Both vectors were packaged into the muscle-trophic serotype AAV9 by the Intellectual and Developmental Disabilities Research Center Neuroconnectivity Core at Baylor College of Medicine. After being titered, viruses were aliquoted (1 Ã 10<sup>13</sup> viral genome particles per tube), immediately frozen, and stored long-term at â80Â°C. Each aliquot was diluted in saline to make a 120 ul injection solution.</p></sec><sec id="s4-8"><title>Echocardiography</title><p>For cardiac function analysis, echocardiography was performed on a VisualSonics Vevo 2100 system with a 550 s probe. B-mode images and M-mode images were captured on a short-axis projection. Ejection fraction, fractional shortening, diameter of diastolic left ventricle, diameter of systolic left ventricle, and end-diastolic volume were calculated by using a cardiac measurement package installed in the Vevo2100 system.</p></sec><sec id="s4-9"><title>Histology and immunofluorescence staining</title><p>Hearts were fixed in 4% paraformaldehyde overnight at 4Â°C, dehydrated in serial ethanol and xylene solutions, and embedded in paraffin. For immunofluorescence staining, slides were sectioned at 7 Î¼m intervals. For paraffin sections, samples were deparaffinized and rehydrated, treated with 3% H<sub>2</sub>O<sub>2</sub> in EtOH and then with antigen retrieval solution (Vector Laboratories Inc, Burlingame, CA, USA), blocked with 10% donkey serum in phosphate-buffered saline, and incubated with primary antibodies. Antibodies used were rabbit anti-HA (#3724, Cell Signaling, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1549585">AB_1549585</ext-link>) and rat anti-flag (NBP1-06712, Novus Biologicals, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:AB_1625981">AB_1625981</ext-link>). Immunofluorescence-stained images were captured on a Zeiss LSM 780 NLO Confocal/2-photon microscope.</p></sec><sec id="s4-10"><title>Statistical analysis</title><p>Sample sizes for mice experiments were determined based on power calculations using preliminary data, with the goal of achieving at least 80% statistical power at a significance level of 0.05. Mice were randomly assigned to experimental groups. For <italic>in vitro</italic> studies, samples were randomly distributed across treatment groups based on initial cell density or viability. Investigators were blinded to group assignments during data collection and analysis to reduce potential bias. Inclusion and exclusion criteria were pre-established before the experiments. Animals or samples were excluded from analysis if they exhibited procedural complications (e.g., unexpected mortality unrelated to the intervention, or technical failure such as injection leakage). The number of biological replicates (n), statistical tests used, and significance thresholds are indicated in the figure legends and throughout the manuscript.</p><p>For the data in this article, the specific statistical test used is presented in the figure legend. In snRNA-seq analyses, Yap score differences between AT1 from Control and COVID-19 patients were identified via the Wilcoxon test. For analyzing iPSC-CMs infected with SARS-CoV-2, the expression score of cardiomyocyte YAP targets was evaluated by Studentâs <italic>t</italic>-test. Mouse survival rates in <xref ref-type="fig" rid="fig2">Figure 2D</xref> were analyzed by the log-rank (MantelâCox) test. Statistical significances were evaluated using three-way ANOVA and Å Ã­dÃ¡kâs multiple comparisons test for other cardiac data, including EF, FS, and systolic LV diameter. For reporter assays in cells and heart/body ratio in <xref ref-type="fig" rid="fig2s6">Figure 2âfigure supplement 6</xref>, the statistical significance of the observed differences in mean was evaluated using a one-way or two-way ANOVA and the post hoc Tukeyâs multiple comparisons test. p-Values &lt;0.05 were considered statistically significant (*p&lt;0.05, **p&lt;0.01, ***p&lt;0.001, ****p&lt;0.0001).</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>founder and owns shares in Yap Therapeutics, and is a co-inventor on the following patents associated with this study: patent no. US20200206327A1 entitled &quot;Hippo pathway deficiency reverses systolic heart failure post-infarction,&quot; patent no.15/642200.PCT/US2014/ 069349 101191411 entitled &quot;Hippo and dystrophin complex signaling in cardiomyocyte renewal,&quot; and patent no. 15/102593.PCT/US2014/069349 9732345 entitled &quot;Hippo and dystrophin complex signaling in cardiomyocyte renewal.&quot;</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Supervision, Funding acquisition, Validation, Investigation, Methodology, Writing â original draft, Project administration, Writing â review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Formal analysis</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Validation</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Methodology</p></fn><fn fn-type="con" id="con5"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Investigation</p></fn><fn fn-type="con" id="con8"><p>Validation</p></fn><fn fn-type="con" id="con9"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Validation</p></fn><fn fn-type="con" id="con11"><p>Investigation, Methodology</p></fn><fn fn-type="con" id="con12"><p>Conceptualization, Resources, Project administration, Writing â review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-100248-mdarchecklist1-v1.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>IP-MS raw data.</title></caption><media xlink:href="elife-100248-data1-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>IP-MS analysis.</title></caption><media xlink:href="elife-100248-data2-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata3"><label>Source data 3.</label><caption><title>STRING analysis.</title></caption><media xlink:href="elife-100248-data3-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material><supplementary-material id="sdata4"><label>Source data 4.</label><caption><title>Supporting data values in figures.</title></caption><media xlink:href="elife-100248-data4-v1.xlsx" mimetype="application" mime-subtype="xlsx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All the sequencing data in Figure 1 and Figure 1âfigure supplements 1â4 were downloaded from two published papers (GSE171668 and GSE171524). Source data 4 (Supporting data values excel) contains the numerical data used to generate the figures. Source datas 1â3 provide raw data and analysis of mass spectrum.</p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset1"><person-group person-group-type="author"><name><surname>Delorey</surname><given-names>TM</given-names></name><name><surname>Ziegler</surname><given-names>CGK</given-names></name><name><surname>Heimberg</surname><given-names>G</given-names></name><name><surname>Normand</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Segerstolpe</surname><given-names>A</given-names></name><name><surname>Abbondanza</surname><given-names>D</given-names></name><name><surname>Fleming</surname><given-names>SJ</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Montoro</surname><given-names>DT</given-names></name><name><surname>Jagadeesh</surname><given-names>KA</given-names></name><name><surname>Dey</surname><given-names>KK</given-names></name><name><surname>Sen</surname><given-names>P</given-names></name><name><surname>Slyper</surname><given-names>M</given-names></name><name><surname>Pita-Juarez</surname><given-names>YH</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Bloom-Ackermann</surname><given-names>Z</given-names></name><name><surname>Barkas</surname><given-names>N</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>J</given-names></name><name><surname>Melms</surname><given-names>JC</given-names></name><name><surname>Katsyv</surname><given-names>I</given-names></name><name><surname>Normandin</surname><given-names>E</given-names></name><name><surname>Naderi</surname><given-names>P</given-names></name><name><surname>Popov</surname><given-names>YV</given-names></name><name><surname>Raju</surname><given-names>SS</given-names></name><name><surname>Niezen</surname><given-names>S</given-names></name><name><surname>Tsai</surname><given-names>LT</given-names></name><name><surname>Siddle</surname><given-names>KJ</given-names></name><name><surname>Sud</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>VM</given-names></name><name><surname>Vellarikkal</surname><given-names>SK</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Amir-Zilberstein</surname><given-names>L</given-names></name><name><surname>Atri</surname><given-names>DS</given-names></name><name><surname>Beechem</surname><given-names>J</given-names></name><name><surname>Brook</surname><given-names>OR</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Divakar</surname><given-names>P</given-names></name><name><surname>Dorceus</surname><given-names>P</given-names></name><name><surname>Engreitz</surname><given-names>JM</given-names></name><name><surname>Essene</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>DM</given-names></name><name><surname>Fropf</surname><given-names>R</given-names></name><name><surname>Gazal</surname><given-names>S</given-names></name><name><surname>Gould</surname><given-names>J</given-names></name><name><surname>Grzyb</surname><given-names>J</given-names></name><name><surname>Harvey</surname><given-names>T</given-names></name><name><surname>Hecht</surname><given-names>J</given-names></name><name><surname>Hether</surname><given-names>T</given-names></name><name><surname>Jane-Valbuena</surname><given-names>J</given-names></name><name><surname>Leney-Greene</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>McCabe</surname><given-names>C</given-names></name><name><surname>McLoughlin</surname><given-names>DE</given-names></name><name><surname>Miller</surname><given-names>EM</given-names></name><name><surname>Muus</surname><given-names>C</given-names></name><name><surname>Niemi</surname><given-names>M</given-names></name><name><surname>Padera</surname><given-names>R</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Pant</surname><given-names>D</given-names></name><name><surname>Pe'er</surname><given-names>C</given-names></name><name><surname>Pfiffner-Borges</surname><given-names>J</given-names></name><name><surname>Pinto</surname><given-names>CJ</given-names></name><name><surname>Plaisted</surname><given-names>J</given-names></name><name><surname>Reeves</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>M</given-names></name><name><surname>Rudy</surname><given-names>M</given-names></name><name><surname>Rueckert</surname><given-names>EH</given-names></name><name><surname>Siciliano</surname><given-names>M</given-names></name><name><surname>Sturm</surname><given-names>A</given-names></name><name><surname>Todres</surname><given-names>E</given-names></name><name><surname>Waghray</surname><given-names>A</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zollinger</surname><given-names>DR</given-names></name><name><surname>Cosimi</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>RM</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Hide</surname><given-names>W</given-names></name><name><surname>Price</surname><given-names>AL</given-names></name><name><surname>Rajagopal</surname><given-names>J</given-names></name><name><surname>Tata</surname><given-names>PR</given-names></name><name><surname>Riedel</surname><given-names>S</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name><name><surname>Tickle</surname><given-names>TL</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Hung</surname><given-names>D</given-names></name><name><surname>Sabeti</surname><given-names>PC</given-names></name><name><surname>Novak</surname><given-names>R</given-names></name><name><surname>Rogers</surname><given-names>R</given-names></name><name><surname>Ingber</surname><given-names>DE</given-names></name><name><surname>Jiang</surname><given-names>ZG</given-names></name><name><surname>Juric</surname><given-names>D</given-names></name><name><surname>Babadi</surname><given-names>M</given-names></name><name><surname>Farhi</surname><given-names>SL</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>JR</given-names></name><name><surname>Vlachos</surname><given-names>IS</given-names></name><name><surname>Solomon</surname><given-names>IH</given-names></name><name><surname>Ashenberg</surname><given-names>O</given-names></name><name><surname>Porter</surname><given-names>CBM</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Villani</surname><given-names>AC</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>COVID-19 tissue atlases reveal SARS-COV-2 pathology and cellular targets</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE171668">GSE171668</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Melms</surname><given-names>JC</given-names></name><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Nair</surname><given-names>A</given-names></name><name><surname>Tagore</surname><given-names>S</given-names></name><name><surname>Katsyv</surname><given-names>I</given-names></name><name><surname>Rendeiro</surname><given-names>AF</given-names></name><name><surname>Amin</surname><given-names>AD</given-names></name><name><surname>Schapiro</surname><given-names>D</given-names></name><name><surname>Frangieh</surname><given-names>CJ</given-names></name><name><surname>Luoma</surname><given-names>AM</given-names></name><name><surname>Filliol</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Ravichandran</surname><given-names>Y</given-names></name><name><surname>Clausi</surname><given-names>MG</given-names></name><name><surname>Alba</surname><given-names>GA</given-names></name><name><surname>Rogava</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>SW</given-names></name><name><surname>Ho</surname><given-names>P</given-names></name><name><surname>Montoro</surname><given-names>DT</given-names></name><name><surname>Kornberg</surname><given-names>AE</given-names></name><name><surname>Han</surname><given-names>AS</given-names></name><name><surname>Bakhoum</surname><given-names>MF</given-names></name><name><surname>Anandasabapathy</surname><given-names>N</given-names></name><name><surname>Suarez-Farinas</surname><given-names>M</given-names></name><name><surname>Bakhoum</surname><given-names>SF</given-names></name><name><surname>Bram</surname><given-names>Y</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>XV</given-names></name><name><surname>Lefkowitch</surname><given-names>JH</given-names></name><name><surname>Marboe</surname><given-names>C</given-names></name><name><surname>Lagana</surname><given-names>SM</given-names></name><name><surname>Del Portillo</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>EJ</given-names></name><name><surname>Zorn</surname><given-names>E</given-names></name><name><surname>Markowitz</surname><given-names>GS</given-names></name><name><surname>Schwabe</surname><given-names>RF</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Saqi</surname><given-names>A</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Que</surname><given-names>J</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Columbia University/NYP COVID-19 Lung Atlas</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE171524">GSE171524</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We are grateful to Drs. Nevan J Krogan and Pinglong Xu for the plasmid gifts. Dr. Hongxin Guan assisted with NSP13 mutant structure analysis. Rebecca Bartow, PhD, of the Department of Scientific Publications at The Texas Heart Institute, provided editorial support. National Institutes of Health grant HL 127717 (JFM). National Institutes of Health grant HL 130804 (JFM). National Institutes of Health grant HL 118761 (JFM). Vivian L Smith Foundation (JFM). 2020 COVID-19 RFA (JFM). AHA postdoctoral fellowship 903411 (FM). AHA Career Development Award 24CDA1274610 (FM). AHA postdoctoral fellowship 903651 (RL). K99 HL169742 (JS). Don McGill Gene Editing Laboratory of The Texas Heart Institute (XL).</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Malone</surname><given-names>B</given-names></name><name><surname>Llewellyn</surname><given-names>E</given-names></name><name><surname>Grasso</surname><given-names>M</given-names></name><name><surname>Shelton</surname><given-names>PMM</given-names></name><name><surname>Olinares</surname><given-names>PDB</given-names></name><name><surname>Maruthi</surname><given-names>K</given-names></name><name><surname>Eng</surname><given-names>ET</given-names></name><name><surname>Vatandaslar</surname><given-names>H</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>Kapoor</surname><given-names>TM</given-names></name><name><surname>Darst</surname><given-names>SA</given-names></name><name><surname>Campbell</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Structural basis for helicase-polymerase coupling in the SARS-CoV-2 replication-transcription complex</article-title><source>Cell</source><volume>182</volume><fpage>1560</fpage><lpage>1573</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.07.033</pub-id><pub-id pub-id-type="pmid">32783916</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Malone</surname><given-names>B</given-names></name><name><surname>Llewellyn</surname><given-names>E</given-names></name><name><surname>Pechersky</surname><given-names>Y</given-names></name><name><surname>Maruthi</surname><given-names>K</given-names></name><name><surname>Eng</surname><given-names>ET</given-names></name><name><surname>Perry</surname><given-names>JK</given-names></name><name><surname>Campbell</surname><given-names>EA</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name><name><surname>Darst</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Ensemble cryo-EM reveals conformational states of the nsp13 helicase in the SARS-CoV-2 helicase replication-transcription complex</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>29</volume><fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/s41594-022-00734-6</pub-id><pub-id pub-id-type="pmid">35260847</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Felice</surname><given-names>FG</given-names></name><name><surname>Tovar-Moll</surname><given-names>F</given-names></name><name><surname>Moll</surname><given-names>J</given-names></name><name><surname>Munoz</surname><given-names>DP</given-names></name><name><surname>Ferreira</surname><given-names>ST</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System</article-title><source>Trends in Neurosciences</source><volume>43</volume><fpage>355</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/j.tins.2020.04.004</pub-id><pub-id pub-id-type="pmid">32359765</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delorey</surname><given-names>TM</given-names></name><name><surname>Ziegler</surname><given-names>CGK</given-names></name><name><surname>Heimberg</surname><given-names>G</given-names></name><name><surname>Normand</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Segerstolpe</surname><given-names>Ã</given-names></name><name><surname>Abbondanza</surname><given-names>D</given-names></name><name><surname>Fleming</surname><given-names>SJ</given-names></name><name><surname>Subramanian</surname><given-names>A</given-names></name><name><surname>Montoro</surname><given-names>DT</given-names></name><name><surname>Jagadeesh</surname><given-names>KA</given-names></name><name><surname>Dey</surname><given-names>KK</given-names></name><name><surname>Sen</surname><given-names>P</given-names></name><name><surname>Slyper</surname><given-names>M</given-names></name><name><surname>Pita-JuÃ¡rez</surname><given-names>YH</given-names></name><name><surname>Phillips</surname><given-names>D</given-names></name><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Bloom-Ackermann</surname><given-names>Z</given-names></name><name><surname>Barkas</surname><given-names>N</given-names></name><name><surname>Ganna</surname><given-names>A</given-names></name><name><surname>Gomez</surname><given-names>J</given-names></name><name><surname>Melms</surname><given-names>JC</given-names></name><name><surname>Katsyv</surname><given-names>I</given-names></name><name><surname>Normandin</surname><given-names>E</given-names></name><name><surname>Naderi</surname><given-names>P</given-names></name><name><surname>Popov</surname><given-names>YV</given-names></name><name><surname>Raju</surname><given-names>SS</given-names></name><name><surname>Niezen</surname><given-names>S</given-names></name><name><surname>Tsai</surname><given-names>LT-Y</given-names></name><name><surname>Siddle</surname><given-names>KJ</given-names></name><name><surname>Sud</surname><given-names>M</given-names></name><name><surname>Tran</surname><given-names>VM</given-names></name><name><surname>Vellarikkal</surname><given-names>SK</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Amir-Zilberstein</surname><given-names>L</given-names></name><name><surname>Atri</surname><given-names>DS</given-names></name><name><surname>Beechem</surname><given-names>J</given-names></name><name><surname>Brook</surname><given-names>OR</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Divakar</surname><given-names>P</given-names></name><name><surname>Dorceus</surname><given-names>P</given-names></name><name><surname>Engreitz</surname><given-names>JM</given-names></name><name><surname>Essene</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>DM</given-names></name><name><surname>Fropf</surname><given-names>R</given-names></name><name><surname>Gazal</surname><given-names>S</given-names></name><name><surname>Gould</surname><given-names>J</given-names></name><name><surname>Grzyb</surname><given-names>J</given-names></name><name><surname>Harvey</surname><given-names>T</given-names></name><name><surname>Hecht</surname><given-names>J</given-names></name><name><surname>Hether</surname><given-names>T</given-names></name><name><surname>JanÃ©-Valbuena</surname><given-names>J</given-names></name><name><surname>Leney-Greene</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>McCabe</surname><given-names>C</given-names></name><name><surname>McLoughlin</surname><given-names>DE</given-names></name><name><surname>Miller</surname><given-names>EM</given-names></name><name><surname>Muus</surname><given-names>C</given-names></name><name><surname>Niemi</surname><given-names>M</given-names></name><name><surname>Padera</surname><given-names>R</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Pant</surname><given-names>D</given-names></name><name><surname>Peâer</surname><given-names>C</given-names></name><name><surname>Pfiffner-Borges</surname><given-names>J</given-names></name><name><surname>Pinto</surname><given-names>CJ</given-names></name><name><surname>Plaisted</surname><given-names>J</given-names></name><name><surname>Reeves</surname><given-names>J</given-names></name><name><surname>Ross</surname><given-names>M</given-names></name><name><surname>Rudy</surname><given-names>M</given-names></name><name><surname>Rueckert</surname><given-names>EH</given-names></name><name><surname>Siciliano</surname><given-names>M</given-names></name><name><surname>Sturm</surname><given-names>A</given-names></name><name><surname>Todres</surname><given-names>E</given-names></name><name><surname>Waghray</surname><given-names>A</given-names></name><name><surname>Warren</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zollinger</surname><given-names>DR</given-names></name><name><surname>Cosimi</surname><given-names>L</given-names></name><name><surname>Gupta</surname><given-names>RM</given-names></name><name><surname>Hacohen</surname><given-names>N</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Hide</surname><given-names>W</given-names></name><name><surname>Price</surname><given-names>AL</given-names></name><name><surname>Rajagopal</surname><given-names>J</given-names></name><name><surname>Tata</surname><given-names>PR</given-names></name><name><surname>Riedel</surname><given-names>S</given-names></name><name><surname>Szabo</surname><given-names>G</given-names></name><name><surname>Tickle</surname><given-names>TL</given-names></name><name><surname>Ellinor</surname><given-names>PT</given-names></name><name><surname>Hung</surname><given-names>D</given-names></name><name><surname>Sabeti</surname><given-names>PC</given-names></name><name><surname>Novak</surname><given-names>R</given-names></name><name><surname>Rogers</surname><given-names>R</given-names></name><name><surname>Ingber</surname><given-names>DE</given-names></name><name><surname>Jiang</surname><given-names>ZG</given-names></name><name><surname>Juric</surname><given-names>D</given-names></name><name><surname>Babadi</surname><given-names>M</given-names></name><name><surname>Farhi</surname><given-names>SL</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name><name><surname>Stone</surname><given-names>JR</given-names></name><name><surname>Vlachos</surname><given-names>IS</given-names></name><name><surname>Solomon</surname><given-names>IH</given-names></name><name><surname>Ashenberg</surname><given-names>O</given-names></name><name><surname>Porter</surname><given-names>CBM</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Shalek</surname><given-names>AK</given-names></name><name><surname>Villani</surname><given-names>A-C</given-names></name><name><surname>Rozenblatt-Rosen</surname><given-names>O</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets</article-title><source>Nature</source><volume>595</volume><fpage>107</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03570-8</pub-id><pub-id pub-id-type="pmid">33915569</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>G</given-names></name><name><surname>Jeyachandran</surname><given-names>AV</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Irudayam</surname><given-names>JI</given-names></name><name><surname>Cario</surname><given-names>SC</given-names></name><name><surname>Sen</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Kumar</surname><given-names>A</given-names></name><name><surname>Nielsen-Saines</surname><given-names>K</given-names></name><name><surname>French</surname><given-names>SW</given-names></name><name><surname>Shah</surname><given-names>PS</given-names></name><name><surname>Morizono</surname><given-names>K</given-names></name><name><surname>Gomperts</surname><given-names>BN</given-names></name><name><surname>Deb</surname><given-names>A</given-names></name><name><surname>Ramaiah</surname><given-names>A</given-names></name><name><surname>Arumugaswami</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hippo signaling pathway activation during SARS-CoV-2 infection contributes to host antiviral response</article-title><source>PLOS Biology</source><volume>20</volume><elocation-id>e3001851</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.3001851</pub-id><pub-id pub-id-type="pmid">36346780</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gokey</surname><given-names>JJ</given-names></name><name><surname>Snowball</surname><given-names>J</given-names></name><name><surname>Sridharan</surname><given-names>A</given-names></name><name><surname>Sudha</surname><given-names>P</given-names></name><name><surname>Kitzmiller</surname><given-names>JA</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Whitsett</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>YAP regulates alveolar epithelial cell differentiation and <italic>AGER</italic> via NFIB/KLF5/NKX2-1</article-title><source>iScience</source><volume>24</volume><elocation-id>102967</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2021.102967</pub-id><pub-id pub-id-type="pmid">34466790</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Hao</surname><given-names>S</given-names></name><name><surname>Andersen-Nissen</surname><given-names>E</given-names></name><name><surname>Mauck</surname><given-names>WM</given-names><suffix>III</suffix></name><name><surname>Zheng</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Wilk</surname><given-names>AJ</given-names></name><name><surname>Darby</surname><given-names>C</given-names></name><name><surname>Zager</surname><given-names>M</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Stoeckius</surname><given-names>M</given-names></name><name><surname>Papalexi</surname><given-names>E</given-names></name><name><surname>Mimitou</surname><given-names>EP</given-names></name><name><surname>Jain</surname><given-names>J</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Fleming</surname><given-names>LM</given-names></name><name><surname>Yeung</surname><given-names>B</given-names></name><name><surname>Rogers</surname><given-names>AJ</given-names></name><name><surname>McElrath</surname><given-names>JM</given-names></name><name><surname>Blish</surname><given-names>CA</given-names></name><name><surname>Gottardo</surname><given-names>R</given-names></name><name><surname>Smibert</surname><given-names>P</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Integrated analysis of multimodal single-cell data</article-title><source>Cell</source><volume>184</volume><fpage>3573</fpage><lpage>3587</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2021.04.048</pub-id><pub-id pub-id-type="pmid">34062119</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>KrÃ¼ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>MÃ¼ller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>PÃ¶hlmann</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><volume>181</volume><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.02.052</pub-id><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>AW</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The Hippo pathway in intestinal regeneration and disease</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>13</volume><fpage>324</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1038/nrgastro.2016.59</pub-id><pub-id pub-id-type="pmid">27147489</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huh</surname><given-names>HD</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Jeong</surname><given-names>HS</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regulation of TEAD transcription factors in cancer biology</article-title><source>Cells</source><volume>8</volume><elocation-id>600</elocation-id><pub-id pub-id-type="doi">10.3390/cells8060600</pub-id><pub-id pub-id-type="pmid">31212916</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Ren</surname><given-names>Z</given-names></name><name><surname>Wu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Ming</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Lou</surname><given-names>Z</given-names></name><name><surname>Rao</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis</article-title><source>Nucleic Acids Research</source><volume>47</volume><fpage>6538</fpage><lpage>6550</lpage><pub-id pub-id-type="doi">10.1093/nar/gkz409</pub-id><pub-id pub-id-type="pmid">31131400</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Spencer</surname><given-names>CA</given-names></name><name><surname>Price</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Involvement of transcription termination factor 2 in mitotic repression of transcription elongation</article-title><source>Molecular Cell</source><volume>14</volume><fpage>375</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(04)00234-5</pub-id><pub-id pub-id-type="pmid">15125840</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Korsunsky</surname><given-names>I</given-names></name><name><surname>Millard</surname><given-names>N</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Slowikowski</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>K</given-names></name><name><surname>Baglaenko</surname><given-names>Y</given-names></name><name><surname>Brenner</surname><given-names>M</given-names></name><name><surname>Loh</surname><given-names>PR</given-names></name><name><surname>Raychaudhuri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Fast, sensitive and accurate integration of single-cell data with Harmony</article-title><source>Nature Methods</source><volume>16</volume><fpage>1289</fpage><lpage>1296</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0619-0</pub-id><pub-id pub-id-type="pmid">31740819</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leach</surname><given-names>JP</given-names></name><name><surname>Heallen</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Rahmani</surname><given-names>M</given-names></name><name><surname>Morikawa</surname><given-names>Y</given-names></name><name><surname>Hill</surname><given-names>MC</given-names></name><name><surname>Segura</surname><given-names>A</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hippo pathway deficiency reverses systolic heart failure after infarction</article-title><source>Nature</source><volume>550</volume><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nature24045</pub-id><pub-id pub-id-type="pmid">28976966</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Yin</surname><given-names>Z</given-names></name><name><surname>Teng</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Liang</surname><given-names>K</given-names></name><name><surname>Cheng</surname><given-names>X</given-names></name><name><surname>Xia</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>SARS-CoV-2 nsp13 restricts episomal DNA transcription without affecting chromosomal DNA</article-title><source>Journal of Virology</source><volume>97</volume><elocation-id>e0051223</elocation-id><pub-id pub-id-type="doi">10.1128/jvi.00512-23</pub-id><pub-id pub-id-type="pmid">37347173</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>KC</given-names></name><name><surname>Park</surname><given-names>HW</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Regulation of the hippo pathway transcription factor TEAD</article-title><source>Trends in Biochemical Sciences</source><volume>42</volume><fpage>862</fpage><lpage>872</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2017.09.003</pub-id><pub-id pub-id-type="pmid">28964625</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xie</surname><given-names>Z</given-names></name><name><surname>Price</surname><given-names>DH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A human RNA polymerase II transcription termination factor is a SWI2/SNF2 family member</article-title><source>The Journal of Biological Chemistry</source><volume>273</volume><fpage>25541</fpage><lpage>25544</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.40.25541</pub-id><pub-id pub-id-type="pmid">9748214</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Pan</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CCT3 acts upstream of YAP and TFCP2 as a potential target and tumour biomarker in liver cancer</article-title><source>Cell Death &amp; Disease</source><volume>10</volume><elocation-id>644</elocation-id><pub-id pub-id-type="doi">10.1038/s41419-019-1894-5</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>S</given-names></name><name><surname>Meng</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The hippo pathway: biology and pathophysiology</article-title><source>Annual Review of Biochemistry</source><volume>88</volume><fpage>577</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1146/annurev-biochem-013118-111829</pub-id><pub-id pub-id-type="pmid">30566373</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>C</given-names></name><name><surname>Cong</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 and the digestive system</article-title><source>The American Journal of Gastroenterology</source><volume>115</volume><fpage>1003</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.14309/ajg.0000000000000691</pub-id><pub-id pub-id-type="pmid">32618648</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malone</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Llewellyn</surname><given-names>E</given-names></name><name><surname>Choi</surname><given-names>YJ</given-names></name><name><surname>Olinares</surname><given-names>PDB</given-names></name><name><surname>Cao</surname><given-names>X</given-names></name><name><surname>Hernandez</surname><given-names>C</given-names></name><name><surname>Eng</surname><given-names>ET</given-names></name><name><surname>Chait</surname><given-names>BT</given-names></name><name><surname>Shaw</surname><given-names>DE</given-names></name><name><surname>Landick</surname><given-names>R</given-names></name><name><surname>Darst</surname><given-names>SA</given-names></name><name><surname>Campbell</surname><given-names>EA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structural basis for backtracking by the SARS-CoV-2 replication-transcription complex</article-title><source>PNAS</source><volume>118</volume><elocation-id>e2102516118</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2102516118</pub-id><pub-id pub-id-type="pmid">33883267</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meli</surname><given-names>VS</given-names></name><name><surname>Veerasubramanian</surname><given-names>PK</given-names></name><name><surname>Downing</surname><given-names>TL</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Liu</surname><given-names>WF</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Mechanosensation to inflammation: Roles for YAP/TAZ in innate immune cells</article-title><source>Science Signaling</source><volume>16</volume><elocation-id>eadc9656</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.adc9656</pub-id><pub-id pub-id-type="pmid">37130167</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Melms</surname><given-names>JC</given-names></name><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Nair</surname><given-names>A</given-names></name><name><surname>Tagore</surname><given-names>S</given-names></name><name><surname>Katsyv</surname><given-names>I</given-names></name><name><surname>Rendeiro</surname><given-names>AF</given-names></name><name><surname>Amin</surname><given-names>AD</given-names></name><name><surname>Schapiro</surname><given-names>D</given-names></name><name><surname>Frangieh</surname><given-names>CJ</given-names></name><name><surname>Luoma</surname><given-names>AM</given-names></name><name><surname>Filliol</surname><given-names>A</given-names></name><name><surname>Fang</surname><given-names>Y</given-names></name><name><surname>Ravichandran</surname><given-names>H</given-names></name><name><surname>Clausi</surname><given-names>MG</given-names></name><name><surname>Alba</surname><given-names>GA</given-names></name><name><surname>Rogava</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>SW</given-names></name><name><surname>Ho</surname><given-names>P</given-names></name><name><surname>Montoro</surname><given-names>DT</given-names></name><name><surname>Kornberg</surname><given-names>AE</given-names></name><name><surname>Han</surname><given-names>AS</given-names></name><name><surname>Bakhoum</surname><given-names>MF</given-names></name><name><surname>Anandasabapathy</surname><given-names>N</given-names></name><name><surname>SuÃ¡rez-FariÃ±as</surname><given-names>M</given-names></name><name><surname>Bakhoum</surname><given-names>SF</given-names></name><name><surname>Bram</surname><given-names>Y</given-names></name><name><surname>Borczuk</surname><given-names>A</given-names></name><name><surname>Guo</surname><given-names>XV</given-names></name><name><surname>Lefkowitch</surname><given-names>JH</given-names></name><name><surname>Marboe</surname><given-names>C</given-names></name><name><surname>Lagana</surname><given-names>SM</given-names></name><name><surname>Del Portillo</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>EJ</given-names></name><name><surname>Zorn</surname><given-names>E</given-names></name><name><surname>Markowitz</surname><given-names>GS</given-names></name><name><surname>Schwabe</surname><given-names>RF</given-names></name><name><surname>Schwartz</surname><given-names>RE</given-names></name><name><surname>Elemento</surname><given-names>O</given-names></name><name><surname>Saqi</surname><given-names>A</given-names></name><name><surname>Hibshoosh</surname><given-names>H</given-names></name><name><surname>Que</surname><given-names>J</given-names></name><name><surname>Izar</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>A molecular single-cell lung atlas of lethal COVID-19</article-title><source>Nature</source><volume>595</volume><fpage>114</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03569-1</pub-id><pub-id pub-id-type="pmid">33915568</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>B</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Targeting the Hippo pathway in heart repair</article-title><source>Cardiovascular Research</source><volume>118</volume><fpage>2402</fpage><lpage>2414</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvab291</pub-id><pub-id pub-id-type="pmid">34528077</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monroe</surname><given-names>TO</given-names></name><name><surname>Hill</surname><given-names>MC</given-names></name><name><surname>Morikawa</surname><given-names>Y</given-names></name><name><surname>Leach</surname><given-names>JP</given-names></name><name><surname>Heallen</surname><given-names>T</given-names></name><name><surname>Cao</surname><given-names>S</given-names></name><name><surname>Krijger</surname><given-names>PHL</given-names></name><name><surname>de Laat</surname><given-names>W</given-names></name><name><surname>Wehrens</surname><given-names>XHT</given-names></name><name><surname>Rodney</surname><given-names>GG</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>YAP Partially reprograms chromatin accessibility to directly induce adult cardiogenesis in vivo</article-title><source>Developmental Cell</source><volume>48</volume><fpage>765</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2019.01.017</pub-id><pub-id pub-id-type="pmid">30773489</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moya</surname><given-names>IM</given-names></name><name><surname>Halder</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hippo-YAP/TAZ signalling in organ regeneration and regenerative medicine</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>20</volume><fpage>211</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0086-y</pub-id><pub-id pub-id-type="pmid">30546055</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandi</surname><given-names>R</given-names></name><name><surname>Bhowmik</surname><given-names>D</given-names></name><name><surname>Srivastava</surname><given-names>R</given-names></name><name><surname>Prakash</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Discovering potential inhibitors against SARS-CoV-2 by targeting Nsp13 Helicase</article-title><source>Journal of Biomolecular Structure &amp; Dynamics</source><volume>40</volume><fpage>12062</fpage><lpage>12074</lpage><pub-id pub-id-type="doi">10.1080/07391102.2021.1970024</pub-id><pub-id pub-id-type="pmid">34455933</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Newman</surname><given-names>JA</given-names></name><name><surname>Douangamath</surname><given-names>A</given-names></name><name><surname>Yadzani</surname><given-names>S</given-names></name><name><surname>Yosaatmadja</surname><given-names>Y</given-names></name><name><surname>Aimon</surname><given-names>A</given-names></name><name><surname>BrandÃ£o-Neto</surname><given-names>J</given-names></name><name><surname>Dunnett</surname><given-names>L</given-names></name><name><surname>Gorrie-Stone</surname><given-names>T</given-names></name><name><surname>Skyner</surname><given-names>R</given-names></name><name><surname>Fearon</surname><given-names>D</given-names></name><name><surname>Schapira</surname><given-names>M</given-names></name><name><surname>von Delft</surname><given-names>F</given-names></name><name><surname>Gileadi</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase</article-title><source>Nature Communications</source><volume>12</volume><elocation-id>4848</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-021-25166-6</pub-id><pub-id pub-id-type="pmid">34381037</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishiga</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>DW</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Lewis</surname><given-names>DB</given-names></name><name><surname>Wu</surname><given-names>JC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives</article-title><source>Nature Reviews. Cardiology</source><volume>17</volume><fpage>543</fpage><lpage>558</lpage><pub-id pub-id-type="doi">10.1038/s41569-020-0413-9</pub-id><pub-id pub-id-type="pmid">32690910</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>S</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Dey</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Transcriptional regulation of the hippo pathway: current understanding and insights from single-cell technologies</article-title><source>Cells</source><volume>11</volume><elocation-id>2225</elocation-id><pub-id pub-id-type="doi">10.3390/cells11142225</pub-id><pub-id pub-id-type="pmid">35883668</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Penkala</surname><given-names>IJ</given-names></name><name><surname>Liberti</surname><given-names>DC</given-names></name><name><surname>Pankin</surname><given-names>J</given-names></name><name><surname>Sivakumar</surname><given-names>A</given-names></name><name><surname>Kremp</surname><given-names>MM</given-names></name><name><surname>Jayachandran</surname><given-names>S</given-names></name><name><surname>Katzen</surname><given-names>J</given-names></name><name><surname>Leach</surname><given-names>JP</given-names></name><name><surname>Windmueller</surname><given-names>R</given-names></name><name><surname>Stolz</surname><given-names>K</given-names></name><name><surname>Morley</surname><given-names>MP</given-names></name><name><surname>Babu</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Frank</surname><given-names>DB</given-names></name><name><surname>Morrisey</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Age-dependent alveolar epithelial plasticity orchestrates lung homeostasis and regeneration</article-title><source>Cell Stem Cell</source><volume>28</volume><fpage>1775</fpage><lpage>1789</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2021.04.026</pub-id><pub-id pub-id-type="pmid">33974915</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perez-Bermejo</surname><given-names>JA</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Rockwood</surname><given-names>SJ</given-names></name><name><surname>Simoneau</surname><given-names>CR</given-names></name><name><surname>Joy</surname><given-names>DA</given-names></name><name><surname>Silva</surname><given-names>AC</given-names></name><name><surname>Ramadoss</surname><given-names>GN</given-names></name><name><surname>Flanigan</surname><given-names>WR</given-names></name><name><surname>Fozouni</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Chen</surname><given-names>PY</given-names></name><name><surname>Nakamura</surname><given-names>K</given-names></name><name><surname>Whitman</surname><given-names>JD</given-names></name><name><surname>Hanson</surname><given-names>PJ</given-names></name><name><surname>McManus</surname><given-names>BM</given-names></name><name><surname>Ott</surname><given-names>M</given-names></name><name><surname>Conklin</surname><given-names>BR</given-names></name><name><surname>McDevitt</surname><given-names>TC</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19</article-title><source>Science Translational Medicine</source><volume>13</volume><elocation-id>eabf7872</elocation-id><pub-id pub-id-type="doi">10.1126/scitranslmed.abf7872</pub-id><pub-id pub-id-type="pmid">33723017</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinto</surname><given-names>SM</given-names></name><name><surname>Subbannayya</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Hagen</surname><given-names>L</given-names></name><name><surname>GÃ³rna</surname><given-names>MW</given-names></name><name><surname>Nieminen</surname><given-names>AI</given-names></name><name><surname>BjÃ¸rÃ¥s</surname><given-names>M</given-names></name><name><surname>Espevik</surname><given-names>T</given-names></name><name><surname>Kainov</surname><given-names>D</given-names></name><name><surname>Kandasamy</surname><given-names>RK</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Multi-OMICs landscape of SARS-CoV-2-induced host responses in human lung epithelial cells</article-title><source>iScience</source><volume>26</volume><elocation-id>105895</elocation-id><pub-id pub-id-type="doi">10.1016/j.isci.2022.105895</pub-id><pub-id pub-id-type="pmid">36590899</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pobbati</surname><given-names>AV</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Rubin</surname><given-names>BP</given-names></name><name><surname>Hong</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Therapeutic targeting of TEAD transcription factors in cancer</article-title><source>Trends in Biochemical Sciences</source><volume>48</volume><fpage>450</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2022.12.005</pub-id><pub-id pub-id-type="pmid">36709077</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pocaterra</surname><given-names>A</given-names></name><name><surname>Romani</surname><given-names>P</given-names></name><name><surname>Dupont</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>YAP/TAZ functions and their regulation at a glance</article-title><source>Journal of Cell Science</source><volume>133</volume><elocation-id>jcs230425</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.230425</pub-id><pub-id pub-id-type="pmid">31996398</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>JO</given-names></name><name><surname>Camargo</surname><given-names>FD</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Hippo signalling in the liver: role in development, regeneration and disease</article-title><source>Nature Reviews. Gastroenterology &amp; Hepatology</source><volume>19</volume><fpage>297</fpage><lpage>312</lpage><pub-id pub-id-type="doi">10.1038/s41575-021-00571-w</pub-id><pub-id pub-id-type="pmid">35064256</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Xie</surname><given-names>F</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Dai</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Ling</surname><given-names>L</given-names></name><name><surname>Jia</surname><given-names>J</given-names></name><name><surname>van Dam</surname><given-names>H</given-names></name><name><surname>Jin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>YAP antagonizes innate antiviral immunity and is targeted for lysosomal degradation through IKKÉ-mediated phosphorylation</article-title><source>Nature Immunology</source><volume>18</volume><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1038/ni.3744</pub-id><pub-id pub-id-type="pmid">28481329</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Heallen</surname><given-names>T</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>The Hippo pathway in the heart: pivotal roles in development, disease, and regeneration</article-title><source>Nature Reviews. Cardiology</source><volume>15</volume><fpage>672</fpage><lpage>684</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0063-3</pub-id><pub-id pub-id-type="pmid">30111784</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zou</surname><given-names>F</given-names></name><name><surname>Jin</surname><given-names>Z</given-names></name><name><surname>Zhao</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The hippo pathway and viral infections</article-title><source>Frontiers in Microbiology</source><volume>10</volume><elocation-id>3033</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2019.03033</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Ling</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>X</given-names></name><name><surname>Chu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The crosstalk between hippo-YAP pathway and innate immunity</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>323</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00323</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Hill</surname><given-names>MC</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Deshmukh</surname><given-names>V</given-names></name><name><surname>Martin</surname><given-names>TJ</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Martin</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hippo pathway deletion in adult resting cardiac fibroblasts initiates a cell state transition with spontaneous and self-sustaining fibrosis</article-title><source>Genes &amp; Development</source><volume>33</volume><fpage>1491</fpage><lpage>1505</lpage><pub-id pub-id-type="doi">10.1101/gad.329763.119</pub-id><pub-id pub-id-type="pmid">31558567</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Jia</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Rao</surname><given-names>Z</given-names></name><name><surname>Lou</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Architecture of a SARS-CoV-2 mini replication and transcription complex</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>5874</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-19770-1</pub-id><pub-id pub-id-type="pmid">33208736</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>L</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Guddat</surname><given-names>LW</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Rao</surname><given-names>Z</given-names></name><name><surname>Lou</surname><given-names>Z</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cryo-EM Structure of an Extended SARS-CoV-2 replication and transcription complex reveals an intermediate state in cap synthesis</article-title><source>Cell</source><volume>184</volume><fpage>184</fpage><lpage>193</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.016</pub-id><pub-id pub-id-type="pmid">33232691</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zeng</surname><given-names>J</given-names></name><name><surname>Weissmann</surname><given-names>F</given-names></name><name><surname>Bertolin</surname><given-names>AP</given-names></name><name><surname>Posse</surname><given-names>V</given-names></name><name><surname>Canal</surname><given-names>B</given-names></name><name><surname>Ulferts</surname><given-names>R</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Harvey</surname><given-names>R</given-names></name><name><surname>Hussain</surname><given-names>S</given-names></name><name><surname>Milligan</surname><given-names>JC</given-names></name><name><surname>Roustan</surname><given-names>C</given-names></name><name><surname>Borg</surname><given-names>A</given-names></name><name><surname>McCoy</surname><given-names>L</given-names></name><name><surname>Drury</surname><given-names>LS</given-names></name><name><surname>Kjaer</surname><given-names>S</given-names></name><name><surname>McCauley</surname><given-names>J</given-names></name><name><surname>Howell</surname><given-names>M</given-names></name><name><surname>Beale</surname><given-names>R</given-names></name><name><surname>Diffley</surname><given-names>JFX</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of nsp13 helicase</article-title><source>The Biochemical Journal</source><volume>478</volume><fpage>2405</fpage><lpage>2423</lpage><pub-id pub-id-type="doi">10.1042/BCJ20210201</pub-id><pub-id pub-id-type="pmid">34198322</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Plouffe</surname><given-names>SW</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Feng</surname><given-names>XH</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hippo signalling governs cytosolic nucleic acid sensing through YAP/TAZ-mediated TBK1 blockade</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>362</fpage><lpage>374</lpage><pub-id pub-id-type="doi">10.1038/ncb3496</pub-id><pub-id pub-id-type="pmid">28346439</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Hippo signaling in the immune system</article-title><source>Trends in Biochemical Sciences</source><volume>43</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.tibs.2017.11.009</pub-id><pub-id pub-id-type="pmid">29249569</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>B</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Udan</surname><given-names>RS</given-names></name><name><surname>Yang</surname><given-names>Q</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Ikenoue</surname><given-names>T</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>P</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Chinnaiyan</surname><given-names>A</given-names></name><name><surname>Halder</surname><given-names>G</given-names></name><name><surname>Lai</surname><given-names>ZC</given-names></name><name><surname>Guan</surname><given-names>KL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control</article-title><source>Genes &amp; Development</source><volume>21</volume><fpage>2747</fpage><lpage>2761</lpage><pub-id pub-id-type="doi">10.1101/gad.1602907</pub-id><pub-id pub-id-type="pmid">17974916</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100248.3.sa0</article-id><title-group><article-title>eLife Assessment</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lim</surname><given-names>Dae-Sik</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Korea Advanced Institute of Science and Technology</institution><country>Republic of Korea</country></aff></contrib></contrib-group><kwd-group kwd-group-type="evidence-strength"><kwd>Compelling</kwd></kwd-group><kwd-group kwd-group-type="claim-importance"><kwd>Important</kwd></kwd-group></front-stub><body><p>This <bold>important</bold> study elucidates the molecular function of the SARS-CoV-2 helicase NSP13, which inhibits the transcriptional activity of the YAP/TEAD complex <italic>in vitro</italic> and <italic>in vivo</italic>. The evidence supporting the authors' claims is <bold>compelling</bold>, based on cell biological assays and multi-omics studies. This work contributes to the understanding of the new regulatory mechanism of YAP/TEAD after SARS-CoV-2 infection and will be of interest to researchers investigating COVID-19 infection and the Hippo-YAP signaling pathway.</p></body></sub-article><sub-article article-type="referee-report" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100248.3.sa1</article-id><title-group><article-title>Reviewer #1 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>In the revised manuscript, Meng et al. report that SARS-CoV-2 infection suppresses YAP target gene transcription in both patient lung samples and iPSC-derived cardiomyocytes. Among the tested viral proteins, the helicase nonstructural protein 13 (NSP13) was identified as a key factor that impairs YAP/TEAD transcriptional activity. Through mutagenesis and protein-protein interaction studies, the authors propose a mechanism where NSP13 binds YAP/TEAD complex, remodels chromatin structure, and recruits transcriptional repressors to inhibit YAP/TEAD's transcriptional activity.</p><p>Overall, this study uncovers a novel regulation of Hippo signaling by SARS-CoV-2 through NSP13, suggesting a potential role of this growth-related pathway in host innate immune response to viral infection. While these findings are intriguing, future studies are needed to validate the involvement of YAP/TEAD in patient tissues and to assess their potential as therapeutic targets against SARS-CoV-2.</p></body></sub-article><sub-article article-type="referee-report" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100248.3.sa2</article-id><title-group><article-title>Reviewer #2 (Public review):</article-title></title-group><contrib-group><contrib contrib-type="author"><anonymous/><role specific-use="referee">Reviewer</role></contrib></contrib-group></front-stub><body><p>Summary:</p><p>The manuscript by Meng et al. describes a role for the coronavirus helicase NSP13 in the regulation of YAP-TEAD-mediated transcription. The authors present data that NSP13 expression in cells reduces YAP-induced TEAD luciferase reporter activity and that NSP13 transduction in cardiomyocytes blocks hyperactive YAP-mutant phenotypes <italic>in vivo</italic>. Mechanisms by which viral proteins (particularly those from coronaviruses) intersect with cellular signaling events is an important research topic, and the intersection of NSP13 with YAP-TEAD transcriptional activity (independent of upstream Hippo pathway mediated signals) offers new knowledge that is of interest to a broad range of researchers.</p><p>Strengths:</p><p>The manuscript presents convincing data mapping the effects of NSP13 on YAP-TEAD reporter activity to the helicase domain. Moreover, the <italic>in vivo</italic> data demonstrating that NSP13 expression in YAP5SA mouse cardiomyocytes increased survival animal rates, and restored cardiac function is striking and is supportive of the model presented.</p><p>Weaknesses:</p><p>While there are some hints at the mechanisms by which NSP13 regulates YAP-TEAD activity through the identification of NSP13-associated proteins by mass spec, the relationships and functions of these factors in the context of YAP-TEAD regulation requires further study in the future.</p></body></sub-article><sub-article article-type="author-comment" id="sa3"><front-stub><article-id pub-id-type="doi">10.7554/eLife.100248.3.sa3</article-id><title-group><article-title>Author response</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Meng</surname><given-names>Fansen</given-names></name><role specific-use="author">Author</role><aff><institution>Texas Heart Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Kim</surname><given-names>Jong Hwan</given-names></name><role specific-use="author">Author</role><aff><institution>Texas Heart Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Tsai</surname><given-names>Chang-Ru</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Steimle</surname><given-names>Jeffrey D</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Jun</given-names></name><role specific-use="author">Author</role><aff><institution>Texas Heart Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Yufeng</given-names></name><role specific-use="author">Author</role><aff><institution>Texas Heart Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Rich Gang</given-names></name><role specific-use="author">Author</role><aff><institution>Texas Heart Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Bing</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Deshmukh</surname><given-names>Vaibhav</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shijie</given-names></name><role specific-use="author">Author</role><aff><institution>Cincinnati Children's Hospital Medical Center</institution><addr-line><named-content content-type="city">Cincinnati</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Xiao</given-names></name><role specific-use="author">Author</role><aff><institution>Texas Heart Institute</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib><contrib contrib-type="author"><name><surname>Martin</surname><given-names>James F</given-names></name><role specific-use="author">Author</role><aff><institution>Baylor College of Medicine</institution><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>The following is the authorsâ response to the original reviews.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #1 (Public Review):</bold></p><p>Major points</p><p>(1) The authors discovered a novel regulation of the Hippo-YAP pathway by SARS-CoV-2 infection but did not address the pathological significance of this finding. It remains unclear why YAP downstream gene transcription needs to be inhibited in response to SARS-CoV-2 infection. Is this inhibition crucial for the innate immune response to SARS-CoV-2? The authors should re-analyze their snRNA-seq and bulk RNA-seq data described in Figure 1 to determine whether any of the affected YAP downstream genes are involved in this process.</p></disp-quote><p>We appreciate the reviewerâs suggestion to clarify the pathological significance of YAP pathway inhibition in SARS-CoV-2 infection. To address this, we re-analyzed our snRNA-seq and bulk RNA-seq datasets to determine whether YAP target genes overlap with known mediators of the innate immune response. As described in Fig. 1C, bulk RNA-seq revealed decreased expression of multiple YAP downstream targets linked to innate immune regulation (e.g., Thbs1, Ccl2, Axl, and Csf1) in SARS-CoV-2âinfected cells <italic>in vitro</italic>.</p><p>snRNA-seq of alveolar type I (AT1) cells from COVID-19 patients revealed a more complex landscape: While we observed reduced YAP activity overall (Fig. 1G), multiple YAP target genes involved in innate immunity and cytokine signaling were paradoxically elevated (Supplemental Fig. 1E). Several factors likelt explain these conflicting observations: 1. In the lung, AT1 cells (which are critical for gas exchange) may cell specifically respond to virus infection by upregulating genes related to immune response by other signaling pathway(s); 2. <italic>In vivo</italic>, SARS-CoV-2 infection triggers a surge in cytokines, chemokines, and other local factors that can differentially modulate YAP binding sites and thus affect its downstream targets, a complexity not fully captured <italic>in vitro</italic>; 3. YAP is highly sensitive to mechanical signals and tissue architecture. The 3D structure of altered cellâcell junctions in infected lung tissue, and fluid shear stress in the alveolar space could shape YAP target gene transcription differently from simplified monolayer cell cultures.</p><p>We have expanded the results section of the new version to include the above points. We also acknowledge that ongoing and future work is needed to delineate the exact molecular and tissue-specific pathways through which YAP inhibition confers a potential advantage in combating SARS-CoV-2.</p><disp-quote content-type="editor-comment"><p>(2) The authors concluded that helicase activity is required for NSP13-induced inhibition of YAP transcriptional activity based on mutation studies (Figure 3B). This finding is somewhat confusing, as K131, K345/K347, and R567 are all essential residues for NSP13 helicase activity while mutating K131 did not affect NSP13's ability to inhibit YAP (Figure 3B). Additionally, there are no data showing exactly how NSP13 inhibits the YAP/TEAD complex through its helicase function. This point was also not reflected in their proposed working model (Figure 4H).</p></disp-quote><p>We appreciate the reviewerâs concerns regarding the helicaseâdependent inhibition of YAP by NSP13, particularly the roles of K131, K345/K347, and R567. Based on published structural and biochemical studies, each of these residues uniquely supports helicase function (1): K131 is crucial for stabilizing the NSP13 stalk region by interacting with S424. Substituting K131 with alanine (K131A) reduces helicase efficiency but does not completely abolish it; K345/K347 are key DNAâbinding residues, and mutating both (K345A/K347A) largely prevents NSP13 from binding DNA, thus eliminating unwinding. R567 is critical for ATP hydrolysis, and the R567A mutant retains DNA binding capacity but fails to unwind it. In Fig. 3B, K131A suppresses YAP transactivation to nearly the same extent as wildâtype NSP13, suggesting that partial helicase activity is sufficient for complete YAP/TEAD inhibition. Conversely, the K345A/K347A and R567A mutants show markedly diminished repression, underscoring the importance of DNA binding and ATP hydrolysis.</p><p>As the new Fig. 4J illustrates, NSP13 must bind DNA and hydrolyze ATP to unwind nucleic acids. This helicaseâdependent process likely enables NSP13 to remodel chromatin structure by binding TEAD and properly organize YAP repressors at YAP/TEAD complex to prevent YAP/TEAD transactivation. In support of this mechanism, the K345A/K347A mutant, unable to anchor to DNA, fails to repress YAP and slightly increases YAPâdriven transcription (Fig. 3B), presumably by mislocalizing YAP repressors. Likewise, the ATPaseâdead R567A can bind DNA but does not unwind and remodel chromatin to recruit YAP repressors, resulting in a loss of YAP suppression (Fig. 3B and 3F). Our revised model demonstrates that both DNA binding and ATPâdependent unwinding are essential for NSP13 to suppress YAP transcriptional activity. We have updated the results, discussion, and model accordingly.</p><disp-quote content-type="editor-comment"><p>(3) The proposed model that NSP13 binds TEAD4 to recruit repressor proteins and inhibits YAP/TEAD downstream gene transcription (Figure 4H) needs further characterization. Second, NSP13 is a DNA-binding protein, and its nucleic acid-binding mutant K345A/K347A failed to inhibit YAP transcriptional activity (Figure 3B). The authors should investigate whether NSP13 could bind to the TEAD binding sequence or the nearby sequence on the genome to modulate TEAD's DNA binding ability. Third, regarding the identified nuclear repressors, the authors should validate the interaction of NSP13 with the ones whose loss activates YAP transcriptional activity (Figure 4G). Lastly, why can't NSP13 bind TEAD4 in the cytoplasmic fractionation if both NSP13 and TEAD4 are detected there (Figure 3B)? This finding indicates their interaction is not a direct protein-protein interaction but is mediated by something in the nucleus, such as genomic DNA.</p></disp-quote><p>(1) Low TEAD expression in HEK293T cells: Our IP-MS experiments were performed in HEK293T cells, which, according to the Human Protein Atlas, express TEAD1â4 at comparatively low levels (TEAD1: 16.5, TEAD2: 16.4, TEAD3: 4.9, TEAD4: 38.7 nTPM). In contrast, HeLa cells, where we successfully validated NSP13-mediated YAP suppression (Fig. 4H, Supplementary Fig.5B-D), show higher expression of these TEAD isoforms (TEAD1: 97.1, TEAD2: 27.3, TEAD3: 12.2, TEAD4: 48.1 nTPM). Therefore, insufficient TEAD abundance in HEK293T cells may limit the sensitivity needed to detect TEADâNSP13 interactions in our proteomic screens.</p><p>(2) Transience and potential DNA dependence: Our co-immunoprecipitation (co-IP) experiments (Fig. 4B, Supplementary Fig.4C-E) indicated that NSP13âTEAD4 binding is low-affinity. Under standard IP-MS conditions (which typically do not include chemical cross-linkers or nucleic acids to stabilize transient complexes), weak or short-lived interactions can be lost during washes or sample processing.</p><p>(3). Additional supporting evidence: We carefully checked our IP-MS data and found that the well-known TEAD binding proteins, including CTBP1/2 and GATA4, were pulled down, suggesting TEADâs absence does not rule out an NSP13âTEAD association.</p><p>(3a) We acknowledge that our NSP13 immunoprecipitationâmass spectrometry (IP-MS) did not identify any TEAD proteins (Fig. 4G and IP-MS tables). Several factors likely contributed to this outcome:</p><p>(3b) We sincerely appreciate the reviewerâs insightful suggestion. While we agree that mapping NSP13 occupancy at individual TEAD-binding motifs is valuable, we respectfully consider this to be beyond the scope of the current study. Biochemical and structural work on coronavirus NSP13 shows that it recognizes nucleicâacid substrates primarily through their 5â² singleâstranded overhang and duplex architecture, not through a defined base sequence(2, 3). Accordingly, our data (Fig. 3B and 3F) indicate that DNA binding ability, rather than recognition of a specific motif, enables NSP13 to perform its helicase activity in proximity to TEAD and recruit repressors. Moreover, the DNAâbinding mutant K345A/K347A and the ATPaseâdead mutant R567A both fail to suppress YAP/TEAD transcription despite retaining the ability to interact with TEAD (Fig. 3B). These lossâofâfunction phenotypes demonstrate that NSP13âs chromatin engagement and unwinding activity, rather than sequenceârestricted targeting, are essential for repression. For these reasons, motifâspecific binding assays were not pursued in this revision, but we clarified in the discussion that NSP13âs DNA engagement is likely structural or TEAD-dependent, rather than sequenceâdirected. We also highlighted this as an important avenue for future investigation.</p><p>(3c) To validate the NSP13 interacting proteins from our IP-MS data, we generated plasmids expressing several candidates (CCT3, SMARCD1, EIF4A1, LMNA, TTF2, and YY2) and performed co-IP assays. As predicted, we confirmed the robust interaction between NSP13 and TEAD (Supplemental Fig. 5E). However, these putative nuclear repressors exhibited weak binding to NSP13 compared with TEAD4, suggesting that NSP13 associates with them indirectly, possibly as part of a larger multiprotein complex or depending on the chromatin structure, rather than via direct proteinâprotein interaction (Fig. 4J).</p><p>(3d) We appreciate the reviewerâs question. To investigate whether their association might be DNAâdependent, we performed coâIP experiments using nuclear lysates in the presence or absence of various nucleases: Universal Nuclease (which degrades all forms of DNA and RNA), DNase I (which cleaves both singleâ and doubleâstranded DNA), and RNase H (which selectively cleaves the RNA strand in RNA/DNA hybrids). Our findings revealed that nucleic acid removal did not disrupt the NSP13/TEAD4 interaction (Supplemental Fig.4E), indicating that their binding is not solely mediated by DNA or RNA.</p><disp-quote content-type="editor-comment"><p><bold>Reviewer #2 (Public Review):</bold></p><p>Specific comments and suggestions for improvement of the manuscript:</p><p>(1) NSP13 has been reported to block, in a helicase-dependent manner, episomal DNA transcription (PMID: 37347173), raising questions about the effects observed on the data shown from the HOP-Flash and 8xGTIIC assays. It would be valuable to demonstrate the specificity of the proposed effect of NSP13 on TEAD activation by YAP (versus broad effects on reporter assays) and also to show that NSP13 reduces the function of endogenous YAP-TEAD transcriptional activity (i.e., does ectopic NSP13 expression reduce the expression of YAP induced TEAD target genes in cells).</p></disp-quote><p>We appreciate the reviewerâs comments and have carefully revisited the conclusions from the published paper(4) (PMID: 37347173), which reported that NSP13 suppresses episomal DNA transcription, as evidenced by reduced Renilla luciferase (driven by the herpes simplex virus thymidine kinase promoter) and GFP expression upon coâexpression with NSP13. For our experiments, we used a dualâluciferase assay with Renilla luciferase (under the same promoter) as an internal control. After re-examining our raw Renilla luciferase data (now provided in the supplemental Excel file âSupporting data valueâ), we found that while 100 ng of NSP13 did not affect Renilla luciferase levels, 400 ng of NSP13 reduced them by approximately 50% relative to the YAP5SAâonly group (Supplemental Fig.2B, Fig.3C-D). We observed a similar reduction with NSP13 truncation mutantsâan outcome not fully consistent with the published study (Supplemental Fig.3D, PMID: 37347173). However, unlike their finding of robust episomal DNA suppression, our data indicate that the K345A/K347A mutant of NSP13, which lacks DNAâbinding ability, completely lost its suppressive effect (Fig.3B).</p><p>We performed additional Notch reporter assays to address the concern that NSP13 might nonspecifically inhibit episomal DNA transcription (including the HOPâFlash and 8ÃGTIIC reporters). These experiments revealed that coâexpression of NSP13 with NICD (Notch intracellular domain) does not suppress Notch signaling (Supplemental Fig. 2C), indicating that NSP13 does not globally block all reporter systems. To evaluate whether NSP13 reduces endogenous YAPâTEAD activity, we transiently overexpressed NSP13 WT and its R567A mutant in HeLa cells. However, bulk RNAâseq and qPCR analyses did not reveal a clear decrease in YAP target genes, possibly due to the low transfection efficiency (&lt; 50%, Supplemental Fig.4D). Interestingly, we observed that YAP5SA was predominantly retained in the nucleus upon NSP13 or R567A coâexpression, suggesting that NSP13 (or together with its interacting partners) restricts YAP5SA cytoplasmic shuttling. Future studies will involve stable cell lines expressing NSP13 WT or R567A to better characterize the mechanisms driving YAP5SA nuclear retention and clarify how NSP13 specifically suppresses YAP activity.</p><disp-quote content-type="editor-comment"><p>(2) While the IP-MS experiment may have revealed new regulators of TEAD activity, the data presented are preliminary and inconclusive. No interactions are validated and beyond slight changes in TEAD reporter activity following knockdown, no direct links to YAP-TEAD are demonstrated, and no link to NPS13 was shown. Also, no details are provided about the methods used for the IP-MS experiment, raising some concerns about potential false positive associations within the data.</p></disp-quote><p>We appreciate the reviewerâs feedback regarding our IP-MS findings and acknowledge that additional validation is required to establish definitive links between the identified putative regulators, YAP-TEAD, and NSP13. We have taken the following steps (and plan further experiments) to address these concerns:</p><p>(2a) Co-IP validation: Same with the answer for Reviewer #1 (3c), we generated plasmids expressing several top candidate interactors from the IP-MS data (CCT3, SMARCD1, EIF4A1, LMNA, TTF2, and YY2) and performed direct co-IP assays in a more controlled setting. The results indicated that these putative NSP13 interactors had weaker binding compared to TEAD4, implying that NSP13 may associate with them as part of a larger complex or depending on the chromatin structure rather than through a direct proteinâprotein interaction (Fig. 4J).</p><p>(2b) qPCR validation: Beyond reporter assays for evaluating YAP transactivation after the candidate YAP suppressor knockdown (Fig. 4H and Supplemental Fig. 5C), we performed qPCR to detect YAP activation on endogenous YAP-TEAD target genes (e.g., CTGF CYR61, and AMOTL2) after CCT3 knockdown. Expression of CTGF and CYR61 was higher compared to control (Supplemental Fig. 5D), strengthening the case for an interaction relevant to YAP-TEAD signaling.</p><p>(2c) To investigate how NSP13âinteracting proteins link to the YAP/TEAD complex, we examined the IPâMS dataset and identified several wellâknown YAP and TEAD binding partners, including CTBP1/2 (TEADâbinding), GATA4 (TEADâbinding), and multiple 14â3â3 isoforms (YWHAZ/YWHAB/YWHAH/YWHAQ, YAP binding). These findings suggest that NSP13 may form a larger nuclear complex with YAP/TEAD and associated cofactors. In the future, we will determine whether these putative TEAD regulators also interact with NSP13 under various conditions (e.g., in the presence or absence of DNA) and whether coâexpression of NSP13 influences their association with YAP or TEAD. This approach will clarify how NSP13 might leverage these factors to regulate YAPâTEAD function.</p><p>(2e) For the mass spectrometry experiments, HEK293T cells were transfected with FlagâYAP1, HAâNSP13, or FlagâYAP1 + HAâNSP13 according to the manufacturerâs standard protocols. After nuclear extraction and lysis, the supernatant was incubated with HA magnetic beads to immunoprecipitate (IP) NSP13. The IP samples were subsequently analyzed by mass spectrometry to identify NSP13âassociated proteins (Fig. 4F). Each experimental condition was performed in duplicate to ensure reproducibility. We included an appropriate negative control (FlagâYAP1) and stringent dataâfiltering criteria to minimize false positives. We apologize for not including these details in our original Methods section; in this revised manuscript, we have fully described the number of replicates, the controls used, and our data analysis pipelines.</p></body></sub-article></article>